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ABSTRACT 
 
Background: High mitotic index, high nuclear grade and reticulin distruption are part of 
representative hallmarks of adrenocortical cancer (ACC). A characteristic neutrophil/T-
lymphocytes infiltrate ratio has been often implicated in carcinogenesis, progression and 
clinical outcome of several cancer types. However, its role in adrenal cortical tumors is 
unclear. Histology-based diagnosis may also suffer of a moment of subjectivity due to 
inter- and intra-observer variations. Proteomic studies of malignant tumors represent the 
future both for possible diagnostic and prognostic implication; whole proteome analysis of 
adrenocortical tumors from fresh tissues may represent the lacking piece of puzzling 
management of this tumor.  
Aim: to assess by computerized morphometry morphological features, vascular, 
inflammatory, reticulin and proliferative index pattern in adrenocortical adenomas (ACAs) 
and carcinomas and to assess proteomic profiles from adrenocortical tumors fresh tissues. 
Methods: A single Institution series of 11 ACAs and 18 ACCs samples was analyzed 
using a Kontron-Zeiss KS400 image analyzer. Four consecutive sections 4 µm thick were 
obtained with a total of 250–300 HPF examined for each case. Immunohistochemistry for 
Ki67, reticulin and CD8/CD15 was obtained. To minimize subjectivity, particularly 
relevant when quantitative results are expected, we generated a morphometric model based 
on analysis of volume fractions occupied by Ki67 positive and negative cells (nuclei, 
cytoplasm) and inflammatory compartments (CD15+ granulocytes, CD8+ lymphocytes) 
and reticulin framework surface.  Lastly, the assessment of Ki-67 by computerized 
morphometry was compared with pathologist’s evaluation. 
After sample preparation protocol of 7 ACCs, 5 ACAs and 5 normal adrenal tissue 
samples, difference In Gel Electrophoresis (DIGE) and following the protein spots 
individuation and isolation, Mass Spectrometry, were performed to allow protein 
identification.  
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Results: The volume fraction of Ki-67 positive cells was highest in ACC. The volume 
fraction of nuclei in unit volume and the nuclear/cytoplasmic ratio in both Ki-67 negative 
cells and Ki-67 positive cells were prominent in ACC. The surface fraction of reticulin was 
considerably lower in ACC. Moreover, when comparing morphometric analysis of Ki67+ 
cells to pathologist’s scores, the data of the point grid analysis revealed significantly lower 
values compared to conventional histopathology. These values, once statistically analyzed, 
demonstrated that our morphometric model could improve the sensitivity and specificity of 
Ki-67 evaluation in ACCs and ACAs (reaching 94% of sensitivity, 100% of specificity) 
and also that it cold contribute to a better prognosis definition.  
Proteomics individuated 62% overexpressed proteins in ACCs with respect to ACAs: 
among them vimentin and vitamin D-binding protein resulted the most varied (3.2 and 3-
fold more expressed in ACCs than in ACAs respectively). On the other hand the remaining 
38% of proteins resulted under-expressed in ACCs with regard to ACAs, being cathepsin 
D and aldose reductase both 3-fold less expressed in ACCs than in ACAs. The protein 
profile of ACCs versus normal adrenal tissue was similar (although with slight differences 
in terms of fold variation) to that of ACCs versus ACAs; nonetheless a varied new protein 
(lactate dehydrogenase, 1.8 fold increase in ACCs) with a possible role in tumorigenesis 
and tumor progression, was detected. 
Conclusions: Our computerized morphometric model is simple, lacks observer or 
subjective bias and can be used to supplement objective methods to achieve precise and 
reader-independent quantification of morphological characteristics and histological 
biomarkers of adrenocortical tumors. We speculate that the assessment of inflammatory 
infiltrate may found a place in the diagnostic algorithm of adrenal benign and malignant 
tumors. The promising preliminary results obtained by the proteomic study of ACCs and 
ACAs could contribute to the identification of new histological biomarkers. These data, 
once integrated into a complex algorithm including histological assessment, morphometric 
analysis and clinical data evaluation would easily contribute to create a prognostic 
stratification of ACCs with clear advantages for the clinical management of the disease. 
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INTRODUCTION 
 
Benign and malignant adrenocortical tumors 
 
The cortical component of the adrenal gland consists of three different 
areas called zona glomerulosa, fasciculata and reticularis, each with specific 
hormonal secretion characteristics: the zona glomerulosa secretes 
glucocorticoids, the zona fasciculata mineralocorticoid, the reticularis mainly 
androgens. On the basis of autopsy findings adrenal neoplasms could be 
considered among the most common malignancies, with a prevalence average 
of 2.3% (range 1-8.7%, probably due to the small size of many lesions).1 
Neoplasms of the adrenal cortex are mostly benign (adenomas) and are often 
found incidentally (the so-called adrenal incidentalomas) during diagnostic 
investigations performed for non-adrenal diseases (3-5% of radiological 
examinations); the definition of incidentaloma does not refer to adrenal 
nodules found in patients undergoing investigations for diagnostic workup of 
a known neoplastic disease.2,3 
The prevalence of adrenocortical adenomas (ACAs) increases with age, 
being approximately 0.2% in the young while it is above 7% in patients with 
more than 70 years.4 The increase of the average with the age of the general 
population and the improvement of the resolution of imaging techniques (as 
well as their increased use) will further contribute to the rise of its prevalence 
with a consequent impact on clinical management and healthcare costs.5 In 
clinical practice, the radiological findings of an adrenal incidentaloma can be 
considered a diagnostic "dilemma", particularly for small lesions.6 Although 
the majority of the adrenal lesions turn out to be benign at the end of the 
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diagnostic workup, fifteen to 20% of adrenal incidentalomas are characterized 
by hormonal hypersecretion syndromes (usually hypercortisolism, in 
particular in the subclinical form; much more rarely occur the neoplasms of 
the medullary component called pheochromocytomas, that are not part of this 
topic). If not treated, these syndromes are associated with high morbidity and 
mortality.7,8 Although the radiological parameters considered as distinctive for 
a likely benign adrenal lesion (Hounsfield Unit, HU, for radiodensity less than 
10 at baseline CT scan and rapid washout of contrast medium) are relatively 
characteristic of an adrenal adenoma, not infrequently they are also present in 
malignant lesions, as demonstrated by a study of the Cleveland Clinic in a 
wide series.9 A careful assessment as to whether these lesions with atypical or 
suspicious radiological features are already hyperfunctioning at the diagnosis 
is therefore crucial. Recognizing any potentially evolving lesion (progression 
from a non-secreting to hypersecreting subclinical or clinical form) and 
predicting the growth rate or the possible progression to malignancy are the 
major endpoints for the clinician.  
Concerning the clinical management the most recent guidelines 
recommend, after the diagnosis of an adrenal incidentaloma, a radiological 
control at 6, 12 and 24 months, and even more frequently in cases suspicious 
for malignancy. This impacts undoubtedly the patient's quality of life (stress, 
exposure to ionizing radiation, hospital access both inpatient and Day 
Hospital care) and also the subsequent increase in costs for the National 
Health System. Moreover in consideration of the complexity of the disease 
management, the diagnostic and curative workup of adrenal lesions 
necessitates the involvement of a multidisciplinary team of expert 
endocrinologists, radiologists, surgeons and pathologists. 
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In 2002, the NIH Consensus Conference of the clinical unapparent 
adrenal mass strongly recommended that adrenal masses larger than 6 cm 
should be surgically removed, suggesting instead a conservative approach for 
adrenal tumors with less than 4 cm size; for the approach to intermediate size 
lesions the indication was to consider additional diagnostic and clinical 
criteria.10 Actually these additional criteria are not sufficiently standardized 
nor widely established. Moreover in view of the increased frequency of the 
diagnosis of ACCs of small size, where surgery would be potentially curative, 
the above described scenario becomes even more complex, as recently 
documented by a review of the National Cancer Data Base.11 This study 
concluded that not even the size of an adrenocortical carcinoma (ACC), 
previously considered as a significant prognostic parameter, correlates with 
long-term survival of patients. On the other hand the presence of regional and 
distant metastases, the nearby surrounding organs invasion and the grading of 
the tumor appeared to be related to worst prognosis. Nonetheless the size of 
the adrenal mass at CT or MRI remains currently one of the best indicators of 
malignancy available. In fact, more than 60% of incidentalomas with a 
diameter less than or equal to 4 cm consists of benign adenomas, while less 
than 2% are carcinomas. On the contrary, the risk of ACC increases up to 
25% in case of lesions larger than 6 cm, while adenomas are less than 15% 
and finally nearly 6% of the nodules between 4 and 6 cm size turns out to be 
malignant.12,10 
The histological diagnosis of the majority of operated adrenal 
incidentalomas is represented by ACAs; more uncommon are their oncocytic 
variant (presenting a clinical-biological attitude slightly more aggressive than 
conventional adenomas). About 5% of the surgically removed incidentalomas 
is represented by pheochromocytomas, while about 2% are adrenal metastases 
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from other undetected cancers. Other categories such as myelolipomas, 
lipomas, cysts, hemangiomas, angiosarcomas and lymphomas are pretty 
rare.13,14,15,16  
The ACC (with all its histological variants) represents the remaining 
5% of these lesions (both incidentally and non-incidentally discovered); this 
rare malignancy has a heterogeneous and only partially known pathogenesis 
and it is associated to a very poor prognosis. Its prevalence is 4-12 cases per 
million adults and an incidence of 1-2 new cases per million per year. Women 
seem to be more affected than men (ratio 1.5), but this difference could be 
partly explained by the fact that women tend to undergo diagnostic tests more 
frequently than men. The ACC is characterized by a bimodal distribution, 
with a first frequency peak in children aged less than five years and a second 
peak in adults in the fourth and fifth decade of life; in children, the incidence 
is 10 times lower, except in some areas of southern Brazil where it has been 
described a high incidence of a germline mutation (in the gene encoding p53) 
implicated in its pathogenesis.12 
Due to the advanced stage of disease at diagnosis, the survival rate of 
patients at 5 years is quite low, ranging from 20% to 45% (with a median 
survival of 18 months); approximately 2/3 of the patients experience a 
recurrence within two years and about 85% of them develop a local 
recurrence or distant metastasis. Moreover about half of patients with ACC 
has already distant metastases at diagnosis: this precludes a surgical approach 
as a possible curative choice.17 Proper staging is therefore essential to 
distinguish subgroups of patients with potentially resectable disease rather 
than eligible to chemotherapy. The most recent revision of the previous 
staging system has been proposed (and nowadays widely applied) by the 
European Network for the Study of Adrenal Tumours (ENS@T)19:  
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Stage I: Disease limited to the adrenal gland with no evidence of local 
invasion or distant metastases, with maximum size of the tumor ≤5 cm 
(T1N0M0) 
Stage II: disease limited to the adrenal gland with no evidence of local 
invasion or distant metastases (like stage I) with maximum size of the tumor 
>5 cm (T2N0M0) 
Stage III: tumor of any size, with at least one of the following 
elements: tumor infiltration into the surrounding tissues (T3), involvement of 
adjacent organs or presence of neoplastic thrombus at the level of the inferior 
vena cava or renal vein (T4), the presence of lymph node metastases (N1) 
without distant metastasis (M0) 
Stage IV: the presence of distant metastases (M1) regardless of the 
tumor size and local extent (T1-T4) and/or of the involvement lymph nodes 
(N0-N1) 
Lesions limited to the adrenal gland (about 30% of adrenal tumors), 
especially when small, still represent a diagnostic problem that often cannot 
be dealt with radiological image alone nor with additional procedures such as 
fine needle biopsy and cytology. In fact fine needle biopsy of an adrenal 
lesion it is no longer indicated as rarely useful due to the ambiguity of the 
cytological results and to the potential risk of tumor cells spreading.20 
Currently this procedure is only used during an oncological workup of a 
primary tumor in case of an adrenal lesion suspicious for metastasis.21 
A careful histologic examination is therefore considered crucial in the 
diagnostic workup of a surgically removed adrenal lesion, in order to make 
appropriate choices for therapy and follow up of an adrenocortical 
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tumor.22,23,24 Since middle of 80s some authors have tried to identify surgical 
and histological parameters capable to predict the clinical behavior of an 
ACC. In 1984 Weiss and coworkers, through a comparative study of 43 cases 
of ACC, identified nine descriptive histological criteria (named "Weisse 
score", see Table 1) able to differentiate with reasonable sensitivity adrenal 
adenomas from carcinomas.25 Unfortunately none of the 9 criteria of the 
Weiss score unequivocally represents per se an absolute feature of 
malignancy. Moreover, due to the heterogeneity of this tumor, Weiss score 
modifications have been proposed accordingly to the different tumor variants 
(classic, oncocytic, myxoid and pediatric), where the classic Weiss criteria 
has been demonstrated not applicable.26 
Morphology and histology of benign and malignant adrenal tumors: 
 
The diagnosis of ACC can be very difficult. First, it is essential to make 
a macroscopic evaluation: in fact the majority of ACCs has a weight greater 
than 100 grams and a diameter greater than 6.5 cm, with presence of 
hemorrhagic areas and/or necrosis and calcifications. These tumors 
commonly have a lobulated aspect, characterized by extensive fibrous septa 
that separate areas of parenchyma, and in some cases involvement of adjacent 
organs may be evident; occasionally a macroscopic angioinvasion could be 
described.27 
In the past the majority of ACCs possessed all the macroscopic features 
described above, including the large size, therefore the diagnosis appeared 
easier already at the first macroscopic evaluation. Serious diagnostic problems 
arose from the increasing number of small adrenal nodules operated that do 
not show the typical macroscopic characteristics of malignancy. The 
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differential diagnosis between one of these “small” ACCs and an adenoma 
can actually be challenging for the pathologists’ routine evaluation.  
Overall the tissue architecture in ACCs is less organized than in 
adenomas, and may remain constant or also vary markedly between different 
areas of the tumor. Normally the organization is in trabeculae, with large 
strings separated by capillary cells, but it is often possible to observe a pattern 
of widespread growth; compact cells are more prevalent in ACCs than in 
adenomas. Nuclear hyperchromatism and pleomorphism is often present in 
ACCs cells, sometimes in presence of multinucleated giant cells. Many of the 
cancerous cells are also characterized by vesicular nuclei with prominent 
nucleoli and nuclear membranes; mitoses are frequent and not rarely 
atypical.28 
Table 1. Weiss Score 
1. High nuclear grade (Fuhrman III or IV) 2. Mitotic index >5/50 High Power Fields 
3. Atypical mitosis 4. Clear cells! 25% of the histological slide 
5. Diffuse architecture >1/3 histological slide 6. Presence of necrosis 
7. Venous invasion 8. Sinusoidal invasion 
9. Tumor capsule invasion  
  
More in detail, mitotic rate is performed with x40 objective by counting 
10 random high power fields (HPF) in the area of the greatest numbers of 
mitotic figures on the five slides with greatest number of mitoses. Atypical 
mitotic figures are regarded as atypical when they definitely show an 
abnormal distribution of chromosomes or an excessive number of mitotic 
spindles.  
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The presence of clear cells is defined as less than or equal to 25% of 
clear or vacuolated cells resembling the normal zona fasciculata. Diffuse 
architecture is observed if greater than one-third of the tumor formed 
patternless sheets of cells: trabecular, columnar, alveolar or nesting 
organizations are regarded as non-diffuse patterns.  
Necrosis is regarded as present when occurring in at least confluent 
nests of cells.  
Concerning vascular invasion (venous or sinusoidal) Weiss defined a 
vein as an “endothelial-lined vessel with smooth muscle as a component of 
the wall and a sinusoid as endothelial-lined vessel in the adrenal gland with 
little supportive tissues”. In case of sinusoids only those located within the 
tumor are considered. 
Invasion of tumor capsule is accepted as present when nests or cords of 
tumor are extended into or through the capsule, with a corresponding stromal 
reaction. 
The Weiss score system as described above has become in the 
following years, till today, the standard method for the evaluation and 
classification of adrenocortical neoplasms also because it does not require 
clinical data (often incomplete or inaccessible for the pathologist) to be 
performed; furthermore, this system allows to obtain information about the 
biological behavior of the lesion, providing important information for the 
therapeutic approach and also contributing to a prognosis assessment. The 
application of the Weiss score however requires experienced pathologists and, 
in consideration of the relative rarity of the disease, several authors agree that 
the interpretation and recognition of some of the histological criteria proposed 
is difficult and operator dependent. Several revisions of this score have been 
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proposed trying to simplify the method and to improve its sensitivity (Van 
Slooten, Hough system), but an adequate standardization is still far to be 
attained. In 2002 Aubert et al. proposed a simplification of Weiss system, 
eliminating the parameters difficult to be assessed and keeping only the most 
reliable and repeatable (Table 2):29  
Table 2. Weiss revisited index, WRI 
1. mitotic Index> 5/50 fields at high resolution (HPF) 
2. Presence of atypical mitosis 
3. Percentage of clear cell ! 25% 
4. Presence of necrosis 
5. Presence of capsular invasion !  
This new system was well correlated with the one proposed by Weiss 
and seemed to be easier to apply in clinical practice. A recent study not only 
confirmed the value of this new system in the diagnosis of the ACC, but also 
showed how it is significantly correlated with the prognosis and in particular 
with patient survival.30 
Following this attempt of Weiss score renovation other authors 
proposed further modifications of the diagnostic algorithm of ACCs: in 2009 
Papotti and coworkers analyzing a large series of ACCs and adenomas found 
that the disruption of the reticular network (defined histologically with 
reticulin staining) was present in all the malignant cases.  Based on this 
finding the authors proposed a new easy-to-perform algorithm where the 
reticulin disruption together with at least one additional parameter (mitotic 
index>5/50 high-power fields (HPF), presence of necrosis and presence of 
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vascular invasion) showed 100% sensitivity and specificity in recognizing 
malignant tumors, also according to the Weiss system, but with more practical 
applicability: this study has been also recently validated in a multicentric 
study in a larger series, showing also a high interobserver reproducibility. 
Immunohistochemistry may also provide important additional information to 
conventional histology in adrenocortical tumor diagnostic workup. Especially, 
the evaluation of proliferative tumor markers (e.g. ki-67) proved to be useful 
in the differential diagnosis between benign and malignant adrenocortical 
neoplasms.31,32,33 
The expression of the protein Ki-67 is closely related to cell 
proliferation, as it is present within the nuclei of cells during all stages of the 
cell cycle (G1, S, G2 and mitosis), but is absent in resting cells (G0);32 the 
protein Ki-67 is considered to be an excellent marker for the assessment of 
the growth fraction of any human cell population (both normal and 
neoplastic), so that the percentage of labeled cells (Ki-67 Labeling Index) is 
commonly used for the diagnosis and evaluation of the "biological behavior" 
of different neoplasms.34,35 As for adrenocortical tumors many studies have 
highlighted the utility of the assessment of Ki-67 expression in clinical 
practice, the labeling index resulting significantly higher in carcinomas than 
adenomas.36,37 Additionally some authors have observed that in patients 
affected by ACC, the Ki-67 Labeling Index (from here on, only Ki-67) is 
inversely related to overall survival. These results suggest that this marker 
may be helpful in identifying patients with more severe prognosis, suggesting 
also a possible role in indicating different therapeutic approaches. A Ki-67 
greater than 5-7% is considered an important clue of malignancy for adrenal 
tumors, although a well-defined cutoff for Ki-67 able to correlate 
unambiguously with the morphology and prognosis of these tumors is not 
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available so far, especially because of a relevant interobserver variability. Ki-
67 is thoroughly studied in breast cancer and Ki-67 immunostaining has been 
shown to be accurately evaluable by computerized methods. Previous studies 
already found that semi-automated analysis of Ki-67 staining with image 
analysis could be used for prognostic assessment of patients with breast 
cancer.38,39,40 
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Computerized morphometry and stereology: state of the art 
 
During the past 30 years, the number of laboratory tests available to be 
used by physicians has grown exponentially. The number and quality of tests 
used in anatomic pathology with the goal of improving the patient care have 
also increased. These technologies range from special histological stains to 
molecular assays at the DNA, RNA, and protein levels. However, 
histopathology remains the gold standard for most diagnostic and therapeutic 
decisions in surgical pathology. Pathologists are increasingly involved in 
clinical practice as part of the team responsible for the management of a 
particular patient and disease. The significant technical improvement of 
former, and the advent of new methodologies gave pathologists also a 
decisional role, especially in oncology. The pathologist judgment is extremely 
important with regard to biomarkers and their cutoff values, presence/absence 
of a particular connotative mutation, infiltrative disease and morphological 
features. In this scenario computerized image analysis and 
morphometric/stereological models could become very helpful. In fact there is 
an expectation in Medicine that the critical part of the operation of an 
instrument should be fully automatic. Indeed, many users express mistrust 
against manual operations, often regarded as subjective and irreproducible. 
Low reproducibility reduces the clinical value of morphologic grading of 
malignant tumors, and the replacement of subjective classification with 
objective quantification has been suggested. 
The interpretation of histologic sections is an inherently subjective 
process based primarily on morphologic features. With the aim of making 
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pathologic examinations less subjective, the extensive use of 
immunohistochemistry (IHC) assisted pathologists in making diagnoses, 
adding to or complementing morphologic information with molecular 
information. Despite the fact that it often lacks reproducibility and 
standardization, immunohistochemistry has become a standard assay in 
surgical pathology. Sources of variability in immunohistochemistry are 
numerous and include fixation conditions, specimen pre-treatment, reagents, 
detection methods, and interpretation of result. With regards to this last point 
the use of the pathologists’ subjective scoring method is less accurate and 
reproducible; Cohen's kappa coefficient, frequently applied as a statistical 
measure of inter-observer agreement for qualitative (categorical) items, still 
shows some pitfalls. Therefore, being impossible the standardization of all the 
potential variables in IHC, a standardizing approach to IHC results through 
quantitative methods has been proposed. More recently, IHC has also been 
used to predict response to targeted therapy. This new role further underlines 
the need of reproducibility and accuracy for this technology.41  
A considerable number of published scientific studies have addressed 
computer vision to quantification of protein expression as determined by 
immunohistochemistry. 42,43,44 Very few studies have compared human visual 
interpretation and computer vision of a biomarker immunostaining with 
regard to clinically important endpoints, such as disease outcome. 45,46  
While tissue sample processing and IHC staining methods are 
increasingly automated, the evaluation of staining results is still 
predominantly performed by visual assessment. A human interpreter has 
excellent image comprehension and pattern recognition capabilities, but is 
prone to substantial variability in quantification tasks. Computer vision 
methods are capable of processing images consistently and generally they 
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perform well in repetitive processes. Virtual microscopy combined with 
computer vision techniques can aid the human observer by analysis of large 
tissue areas at a high magnification. The digital sample (i.e. the virtual slide) 
can be an entire section of a single cancerous tumor or an array of 100-200 
tumor tissue samples assembled by the use of tissue microarray technology.47 
The stereology challenge is to understand the structural inner three-
dimensional arrangement based on the analysis of the structure slices only 
showing two-dimensional information. Through the correct stereology use, a 
quantitative study with little effort could be performed: efficiency in 
stereology means a minimum slices sample counting (little work), low cost 
(slices preparation), but good accuracy. Recently, morphologists have 
benefited of the use of genetic and molecular techniques to help improving 
biological and biomedical researches. However, questions concerning 
quantitative alterations of tissues, cells or cellular organelles (which 
frequently appear in adaptation, evolution or pathology of an organism), as 
well as a better correlation between morphology and function, need a 
quantitative approach to become well understood.48,49 Despite the argument 
about nomenclature morphometry and stereology could denominate the same 
method.50 Most authors consider morphometry as a two-dimensional 
quantitative method that uses a caliper (mainly a caliper micrometer, a gauge 
with a calibrated micrometer screw for the measurement of thin objects under 
microscopic observation). On the contrary, stereology does not use a caliper 
(and does not perform a direct measurement), but it uses a test-system usually 
composed by test-points, test-lines over a known frame (or test-area). Major 
differences between morphometry and stereology are summarized in the table 
here below (modified from Mandarim-de-Lacerda 2003).51 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 19 - 
 
Table 3. Major differences between morphometry and stereology 
Characteristics Morphometry Stereology 
macro, meso, micro levels yes yes 
measurement in the plane yes no 
3-D information no yes 
caliper yes no 
test-system no yes 
unit mm mm/mm3 
slices of the structure not necessarily yes 
formulas simple complex 
probabilistic statistics no yes 
image analysis facilities usually yes usually not 
statistics parametric non parametric !  
Morphometry determines lengths, perimeters, areas, and benefits of 
image analysis software’s facilities. Stereology estimates densities; the most 
interesting are the densities per volume: volume density, length density, 
surface density and numerical density. The accuracy of calculations is based 
on the statistics principles (sample size, randomization, and isotropy). The 
aim of the sampling design for stereology is to obtain the maximal amount of 
quantitative structural information at a given total cost or effort. In general, 
the variation between different individuals (the biological variation) is the 
major determinant of overall efficiency, whereas the variation between single 
microscopic features is less important. However, spending time and/or money 
in order to increase the precision of the single measurements is describe as 
irrational in almost all studies. This could be summarized by the sentence ‘‘do 
more less well’’.52  
Low reproducibility reduces the clinical value of morphologic 
evaluation of malignant tumors: simple mitosis counting has been employed 
for objective malignancy grading most frequently and has proved its 
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prognostic significance in sarcomas and carcinomas of the breast and ovary. 
These and other measurements of morphometry are, however, obtained in two 
dimensions only, introducing bias due to ignorance of the fact that biologic 
structures are three-dimensional. Stereological estimators are well suited, 
because they enable the assessment of spatial structure from sections. It has 
been shown that many stereological evaluations are applicable to ordinary 
histologic sections processed under routine conditions. If a systematic random 
scheme of sampling is employed then the efficiency of estimation is usually 
high and therefore reproducible, accurate and representative results are 
ensured. 
The main problem with instrumental image analysis is that it critically 
depends on image segmentation (detection of the nuclear boundary) as a first 
step, an operation easily resolved in other fields of engineering but that 
represents a formidable obstacle in biology. The prejudice against interactive 
procedures, which so easily would resolve many problems, also appears 
unwarranted in view of the extensive stereological literature proving most 
manual procedures to be efficient. Additionally, all morphometric point 
counting procedures have been consistently proved to be more reliable and 
reproducible than computerized approaches. The unfulfilled promise of image 
analysis in all fields of pathology is that computers would potentially provide 
a dependable, reproducible, and objective instrument of making diagnoses. 
The problem is to find a proper reference system (consider, for instance, the 
stroma, blood vessels, the variable portion of tissue occupied by tumor, even 
the non-stained parts of the tumor cells). Some manufacturers propose to 
quantitate simply by averaging the results over the number of malignant cells. 
This is a conceptually simple approach that belies the difficulty of properly 
segmenting and, therefore, counting nuclei. If not limited by the 
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unfriendliness of the community toward manual and semi-quantitative 
methodologies, a solution would be to limit counts to areas present within an 
adjustable test frame of known area (rather than the entire video screen) and 
to cells identified by a manual approach (clicking on them). Despite this 
interest in morphometric diagnosis, it is evident that, nowadays, the majority 
of diagnoses in pathology are achieved by subjective and visual evaluation.53  
This is generally easy for a trained pathologist, but there are numerous 
cases where an objective quantitative way of resolving a difficult differential 
diagnosis would be welcome, and adrenal tumors are part of this setting. 
Recently virtual microscopy has been proposed to improve histological 
analysis of adrenocortical tumors. In one of these studies twelve pathologists, 
all from reference Centers, analyzed 50 selected adrenocortical tumors using a 
web-based virtual microscopy approach in a blind design and allowed 
determining the intra-observer and inter-observer reproducibility of the Weiss 
system. Interestingly the method was able to very simply grade the intra-
observer reproducibility of every single item: necrosis being the most 
reproducible criteria, whereas sinusoidal invasion resulted almost 
irreproducible. On the other hand nuclear grade and sinusoidal invasion that 
were ruled out of the modified Weiss score proposed by Aubert and 
coworkers because of their low intra-observer reproducibility performed 
poorly also with virtual microscopy. Moreover the two other Weiss criteria 
that were most improved with virtual microscopy were the number of mitotic 
figures and the presence of atypical mitoses: these criteria are among the most 
useful for determining the malignancy and prognosis of ACCs.54 
Overall we could argue that the image analysis–based approach, more 
likely to give rise to a new anatomic subspecialty than to replace pathologist 
evaluation, could only be conceived as one of the ancillary technique at 
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disposal of pathologists. Analysis of the diagnostic approach followed by 
expert pathologists reveals critical reliance on a number of features that can 
be quantified by computerized image analysis, like nuclear size, nuclear 
pleomorphism or chromatin texture. Each of these descriptors could be 
substituted with a quantifiable number, giving the opportunity of creating new 
classification systems and diagnostic algorithms. Morphometric diagnostic 
methods can be applied to both cytology and histology, however cytological 
applications are easier and convincing. In cytology in fact the entire nucleus is 
visible and not just sections of it, nonetheless processing morphometric data 
obtained on histologic sections of paraffin-embedded tissues and achieving a 
diagnosis on them is possible (but it requires considerable adaptation).55  
The procedure that consents a correct histological sample examination 
is segmentation, which designs the delimitation of boundaries between two 
compartments. Once the nucleus has been properly segmented, the following 
computerized measurements inside the nuclear outline (enclosed area, largest 
diameter, intercepts with test lines, even shape factors) by the methods of 
image analysis are easy, straightforward and dependable. Many multipurpose 
graphics programs that can be easily adapted to cytology are commercially 
available. In other words, the quality of the measurements and, therefore, the 
reliability of the diagnosis depend mainly on the nuclear segmentation, which 
is the real Achilles’ heel of diagnostic morphometry.56  
Operator independent and reproducible malignancy grading has interest 
for the clinical pathologist and oncologist, because replacement of subjective 
scoring by quantification offers the potential for improving the accuracy of 
the biologic information provided. Numerous studies have employed 2D 
techniques, and it is known that several morphometric variables may possess 
prognostic impact.57 It seems that especially mitotic counts have strong 
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predictive capacity, in particular in breast and ovary,58,59 and in sarcomas.60 
Objective tumor grading by stereological estimation of the mean nuclear 
volume was first introduced by Nielsen and co-workers in 1986 in a study of 
bladder cancer patients.61 Reviewed by Serrensen six years later this variable 
has been successfully applied to predict the prognosis in a large number of 
tumor types, including malignant melanoma, carcinomas of the uterine cervix, 
oral mucosa,62 and more recently lung carcinoma and carcinoma of the 
ampulla of Vater.63,64 Moreover in breast cancer (and central nervous system 
malignancies as well) evidence is accumulating regarding the value of 
stereological mean nuclear size estimation as a prognostic marker, and also 
stereological application to IHC (e.g. Ki-67) has already emerged as a 
powerful tool able to increase diagnostic and prognostic accuracy in several 
malignancies.65 Many promising studies have been performed also on prostate 
cancer. Ananthanarayanan and coworkers developed an automated method for 
subcellular scoring of p27 without individual segmentation of the cells: this 
method consented to identify a strong relationship between p27 expression 
and prostate cancer recurrence, independent of tumor grade, stage, and 
prostate-specific antigen and regardless of subcellular location. Interestingly 
this relationship was not observed with manual scoring demonstrating an 
improvement of the histological analysis in this cancer thanks to the 
application of an automated model.66  
As for endocrine oncology, several interesting results have been 
obtained with the application of morphometric/stereological models to thyroid 
cytology and histology. In fact due to the difficult identification of malignant 
follicular cells or adjacent normal follicular cells on conventional cytology, 
morphometric parameters could help in pre-surgical diagnosis and or 
simplifying the histological study.67 Some authors found a very strong 
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statistical difference between the morphometric high and low values for area, 
perimeter and large/small nuclear diameter ratio of follicular adenomas and 
carcinomas in agreement with literature data that indicate that the differential 
diagnosis between the two thyroid neoplasms could be based on nuclear 
characteristics, especially nuclear size and perimeter.68,69  
One of the first studies on adrenal disease, particularly on benign and 
malignant pheochromocytomas, demonstrated distribution plots of the 
maximum nuclear cord length and of the nuclear area showing a narrow peak 
for the malignant cases, whereas benign cases showed a right-shifted curve 
with a wider peak: this evidence underlined that nuclear morphometric 
analysis could yield two distinctive patterns and may be of utility in the 
assessment of the diagnosis of the biological behavior of 
pheochromocytomas.70  
Very recently some authors showed how stereology applied to in vitro 
studies of pituitary adenomas is able to give information on basal and 
stimulated/inhibited cell morphology.71  
At present, few data with regard to computerized morphometry 
application on adrenal lesions are available. Some evidences have been 
obtained on age-dependent adrenocortical cell migration and only preliminary 
data on nuclear differences between ACAs and ACCs have been reported. 
Particularly Scarpelli and coworkers several years ago performed a 
quantitative analysis of adrenocortical adenomas and carcinomas: nuclei in 
ACCs resulted larger than in ACAs, total optical density had a near-diploid 
distribution in the adenomas while it was clearly aneuploid in the carcinomas 
and also differences in nuclear chromatin texture were found between the two 
groups. Multivariate analysis showed good discrimination between 
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carcinomas and adenomas and between different histological types of 
adenomas. However, based on Bayesian decision boundaries, 20-25% of 
carcinoma nuclei could be expected to be in the range of adenoma and about 
12% of Cushing's adenomas nuclei and 15% of Conn's adenoma nuclei would 
be classified as carcinoma. This is one of the most crucial results, pointing out 
that the morphological/stereological study per se could be able only partly to 
distinguish between benign and malignant adrenocortical neoplasms, 
suggesting that other tools may be useful, as integrated diagnostic approach, 
to give significant differential morphological information.72 A year later, the 
same group of authors extended the evaluation also to incidentalomas and 
normal adrenal tissue, concluding that computer-assisted analysis of nuclear 
characteristics proved to be useful in identifying and describing differences 
between groups of tumors arising in the adrenal cortex and highlighted the 
similarity between incidentalomas and adjacent normal-appearing cortex and 
between Cushing's adenoma and adrenal carcinoma. Other evidences 
supporting the need of an integrated method emerged also more recently: 
Shirata and coll. evaluated with an image analyzer the chromatin texture of 
pediatric and adulthood ACCs. Although the authors could not show a 
statistical significant correlation of the chromatin texture parameters, they 
were able to demonstrate a marginally significant correlation of DNA-ploidy 
with clinical behavior in children.73 
The precise quantification of morphometric estimators and IHC 
markers is even more important when these parameters are included in 
classification and diagnostic criteria or in prognostic algorithms, as for 
neuroendocrine tumors.74 Precisely for this particular type of endocrine 
tumors a panel of experts indicated the computerized morphometry with 
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digital image analysis as the most reproducible method for the quantification 
of Ki-67 positive cells, although it is not routinely available anywhere.75,76 
The computerized morphometric analysis is not only able to provide 
specific characteristics of cancerous cells, but it could also differentiate 
between the tumor cell compartment and the structures in the surrounding 
microenvironment, especially lymphatic and blood vessels (e.g. interesting for 
the tumor-dependent angiogenesis).77 
Similarly also the intra- and peritumoral inflammatory infiltrate could 
be studied through a morphometric-immunohistochemical approach obtaining 
a more detailed pattern of inflammatory infiltration, already described by 
several authors to be involved with the degree of invasiveness and aggression 
of a particular tumor.78 
Proteomic expression analysis: state of the art 
Proteomics is a methodology extremely vast and complex that, through 
a combination of different technologies, allows identifying, quantifying and 
characterizing all the proteins of a cell, tissue or organism, including those 
still unknown. Proteome analysis has gained considerable attention when the 
human genome has been discovered consisting of far fewer genes than 
expected, disagreeing with the dogma of biology "one gene, one protein". It is 
estimated that approximately 100,000 human genes with mRNA splicing and 
post-translational modifications could generate in humans a proteome of 
nearly 1,000,000 of proteins. The possible applications of proteomics are 
wide and range from the study of the molecular processes that occur in course 
of a disease, such as post-translational modifications of proteins or their 
cellular redistribution, to the exploration of new protein biomarkers specific 
to certain conditions or modified proteins (i.e. phosphorylated, glycosylated, 
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etc.). It is evident in fact that the sole genomic information is not sufficient to 
explain all the biological events and to allow identifying new drug targets. 
The comparison between the protein expression profiles of normal versus 
neoplastic (adenoma, carcinoma) tissue may in fact show a large number of 
hypo- or hyper-expressed proteins, lack or presence of a particular protein, 
and also post-translational modifications. Usually the samples are prepared 
with highly complex protein mixtures such as cell lysates, tissue extracts and 
other biological materials. But it is only with the identification of all the 
proteins in the sample, together with their function, that it would be possible a 
better understanding of the complex mechanism of onset and progression of a 
disease. A large number of studies have reported that there is no single protein 
(so called biomarker) able to discriminate a disease: therefore it is suggested 
to assume that only a combination of biomarkers can better identify a 
particular disease. The ideal marker should be as specific as possible and 
sensitive; it should have clinical utility higher than the one of markers already 
in use, it should be present in biological samples obtained easily through non-
invasive procedures. The liquid biological samples are certainly the most 
suitable for the detection of prognostic or diagnostic biomarkers, thanks to 
their easy accessibility and to the non-invasiveness.  
The sample preparation, prior to its analysis, is one of the most critical 
points of the proteomic study, as it can affect the final results. Some phases of 
proteomic expression analysis cannot be automated, such as sample 
preparation and two-dimensional electrophoresis gel, therefore hiding an 
operator dependent process.79 
The cornerstone of proteomics is the two-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE), used for the separation of proteins according 
to their isoelectric point in the first dimension and to their molecular weight in 
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the second dimension. A 2D-PAGE is able to individuate thousands of 
proteins simultaneously in a single procedure leading theoretically to the 
separation of 10,000 proteins in a single gel. The matching of two 
electrophoretic techniques gives the two-Dimension Electrophoresis (2DE) a 
high-resolution power, making it currently the most powerful separation 
technique for the study of the proteome. This technique obtains information 
on the isoelectric points and molecular weights of proteins, their total amount, 
the protein isoforms and some post-translational modifications. This 
procedure is indicated for the separation of proteins with molecular weights 
between 10 kDa and 100 kDa and isoelectric points between pH 3 and pH 10. 
The 2 DE unfortunately presents some limits, because it is not possible 
expecting for all the proteins contained in a cell to be displayed in a 2-D gel. 
Some proteins with poor solubility will not remain in solution, proteins of 
molecular weight greater than 150 kDa will not enter the first or the second 
dimension, and some of them will be present in quantities too low to be 
visualized. The major limitation is related to the technical difficulties: 
multiple operations are required to achieve a two-dimensional map, therefore 
it is necessary a highly specialized personnel to be in charge of these 
important steps, in order to ensure reproducibility. Some of these problems 
have been eliminated by the introduction of very sophisticated equipment for 
the separation in the first and second dimensions that allow to separate many 
samples simultaneously and to perform fine control on the maintenance of 
conditions of temperature, and current voltage during separations. The sample 
preparation influences the effectiveness of electrophoretic separation: in fact a 
proteome is not a stable mixture, but is constantly changing. The methods of 
sampling and sample preparation are therefore of critical importance to 
preserve the protein composition of the tissue from the time of the extraction 
throughout the rest of the procedure.80 
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A process of preparation of the sample includes four phases: 
- Cell lysate; 
- Sample solubilization; 
- Protease inhibition, to protect the proteins by the action of proteolytic 
enzymes that would lead to their degradation; 
- Impurity removal usually using ultracentrifugation; 
 
  The solubilization procedure must be compatible with the methods of 
analysis used, which can be based on charge differences of the proteins or on 
the mass difference. The proteins are treated with a lyses buffer, consisting of 
a solution containing a mixture of 7M urea and 2M thiourea; this combination 
greatly increases the degree of denaturation and solubilization of proteins. 
Crucial importance is the inclusion of non-ionic detergents, such as CHAPS 
4% and 1% TRITON X100, solubilization in the solution, to completely 
remove the hydrophobic interactions of the protein and to allow the 
solubilization of the greater number of membrane proteins. In fact another 
critical point of the solubilization process is represented by the difficult 
solubilization of hydrophobic membrane proteins that tend to congregate in 
aqueous medium.  
The first dimension separation is obtained through an electrophoretic 
run able to differentiate between the isoelectric points of every single protein; 
it is a high-resolution method capable of separating proteins with isoelectric 
points that differ by 0.01 pH units. The basic requirement for a highly 
reproducible separation is the presence of a stable pH gradient and regular and 
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constant conductivity. Under the effect of an electric field, a protein migrates 
along the gradient toward the point at which its net charge is zero. The use of 
immobilized pH gradient (IPG) strip of thin polyacrylamide, linked to a 
plastic support, has improved the performance and reproducibility of the 
separation. The separation is then obtained by applying a potential difference 
at the ends of a gel containing a pH gradient.81  
With the introduction of Immobiline DryStrips (GE Healthcare), the 
methodology and the manipulation have been made much easier and it 
consents the load of a quantity of proteins up to several milligrams. The 
Immobiline Dry Strips contain a bar code for easy identification of samples. 
The conditions of the electrophoretic run must be precisely controlled. The 
most important parameters are the temperature that must be maintained 
constant at 20°C and the program of applied voltage, which is dependent on 
the length and the pH gradient of the IPG strip. During the run the strips are 
coated with oil to avoid contact with the air and maintain sample under the 
surface. Through a separation platform (e.g. Ettan IPGphor, GE Healthcare) 
12 strips in parallel run are feasible. After separation in the first dimension, 
the strips may be stored in a freezer at -80°C (Figure 1).  
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Figure 1. First dimension Isoelectrofocusing 
Fluorescently labelled proteins are 
separated on gel strip, taking 
advantage in differences of their 
electric charge by isoelectrofocusing 
technique 
 
The second dimension separation (SDS-PAGE) is performed according 
to the protein size. Sodium dodecyl sulfate (SDS) is an ionic detergent. The 
SDS is added to protein samples leading to their degradation and denaturation 
from the original three-dimensional state. All the proteins of the mixture are 
open in a filamentary structure (a molecule of SDS binds every two amino 
acid residues). The sample buffer also contains a tracer (dye) ionizable, 
usually the bromophenol blue, that allows following the trend of the 
electrophoretic run. The SDS-protein complexes, negatively charged, move 
towards the anode under the applied electric field. The smaller the protein, the 
easier is the passage through the pores of the gel, while the larger proteins are 
delayed due to the frictional resistance. The dye bromophenol blue, being a 
small molecule, is absolutely not delayed representing the migration front. 
When the dye reaches the bottom of the gel, current is removed; the gel is 
removed from the two glass plates, kept under stirring for some hours in a dye 
solution suitable for leaving the proteins visible on a transparent background. 
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The techniques commonly used for visualization of proteins fractionated on 
gels are based on the use of dyes that bind indefinitely to any protein.82 
The introduction of fluorescent reagents with sensitivity similar to 
previous reagents as silver staining, but with a linear dynamic range of three 
orders of magnitude, particularly improved the visualization of the proteins. A 
major step forward in terms of sensitivity has been done with the introduction 
of the DIGE (Difference In Gel Electrophoresis), a separation procedure 
described for the first time in 1997 by Unlu and coworkers. This technique 
uses a two-dimensional electrophoresis as an experimental model, but unlike 
the classical 2-D the separation is done within the same gel, with two protein 
extracts labeled with different fluorophores. The fluorophores used as markers 
are structurally similar and do not affect the mobility and electrical charge of 
the proteins (fluorescent cyanine dies: Cy2, Cy3 and Cy5). The DIGE is 
characterized by a degree of sensitivity of 125 pg per single spot of protein, 
presenting a linear response up to five orders of magnitude. The 
reproducibility is guaranteed by the presence of an internal standard that 
represents the protein pattern of all samples that are part of the experiment, 
and which is separated in the same gel with the sample. The internal standard 
increases the precision of matching between the gel and consequently the 
accuracy of the statistical analysis (Figure 2). 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 33 - 
Figure 2. Second dimension SDS-PAGE - DIGE 
In second dimension, gel strips are loaded 
on gel top and proteins separated by 
molecular mass. Spot map images are 
visualized by a scanner laser 
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The polyacrylamide gel used in this technique are prepared inside of 
glass sheets with low emission of fluorescence, the concentration of 
acrylamide being variable from 3% to 20% compared to the total volume of 
the gel. A concentration of 12% (also used in the present study) offers a good 
resolution of proteins between 14 and 100 kD. The scanning of the gel at two 
different wavelengths, which excite the two dye molecules, reveals if each 
individual spot is associated with a single or double dye. Most of the spots 
will have fluorescence emission at both wavelengths, but if a spot is 
associated with a single dye molecule it indicates that the protein is present in 
only one of the biological samples.83  
The modern era of proteomics as a method of molecular 
"fingerprinting" of human tumors was made possible by several technological 
advances: 
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- Genomic sequencing (ie, completion of the first phase of the Human 
Genome Project) and the availability of publicly available databases 
that catalog known protein and nucleic acid sequences 
- Highly sensitive quantitative techniques to detect small amounts of 
protein in biologic samples 
- Laser capture micro-dissection (LCM) technology, which permits the 
isolation of selected cells out of a tissue section 
- Technical advances in mass spectrometry (MS), allowing highly 
sensitive and specific protein identification both in the solubilized 
(liquid) state and in the solid state (ie, directly from tissue samples or 
sections) 
Despite these advances, 2-Dimension Electrophoresis (2-DE) remains 
the foundation of most proteomic studies (particularly investigations of 
biomarkers in serum), because of its ability to separate relatively large 
proteins from biologic materials. With this simple technique and subsequent 
analysis of gel images with specialized software, differences in protein 
expression (eg, presence versus absence, or intensity of different proteins or 
isoforms) between healthy and diseased tissues can be revealed.84 2-DE fails 
to resolve most proteins that are larger than approximately 100 kDa or smaller 
than 5 kDa. Furthermore, 2-DE cannot routinely resolve complex protein 
mixtures into more than 1000 spots.  
Afterwards the proteins of interest can then be identified, typically by 
Mass Spectrometry-based strategies.  
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After the 2D-DIGE gels analysis the process passes to the identification 
of all proteins or only those of specific interest; in most cases, this is done by 
means of peptide mass fingerprint.  
The main aim of a proteomic study is to characterize all the proteins 
expression and the protein identification is the essential endpoint. 
Traditionally the protein patterns in separate 2D gels were identified by 
comparison with protein maps available in reference databases or through 
recognition by specific antibodies. Important progresses in the identification 
of the proteins were made thanks to the development of the techniques of MS. 
A mass spectrometer is a highly accurate instrument that can separate 
individual proteins of very similar molecular weight or mass. MS requires a 
smaller amount of material and has a higher throughput than other sequencing 
methods for protein identification. The goal of applying MS in clinical 
proteomics is to generate protein profiles (mass:charge [m/z] ratio versus 
signal intensity) from body fluids (eg, serum, saliva, urine) or tissue samples 
to detect quantitative and qualitative changes in protein expression levels that 
correlate with the disease states. 
MS operates in the gas phase, and peptides thus must first be ionized; 
the development of newer, gentler ionization methods has led to 
breakthroughs in the application of MS to biotechnology and clinical 
proteomics. Ionization can be accomplished by electrospray ionization for 
solubilized (liquid state) samples, or by laser desorption techniques for 
samples in the solid state. Therefore a “time of flight” analyzer measures the 
ions mass. In simple terms, the MS instrument accelerates the ionized proteins 
across a fixed voltage potential in a high vacuum, measuring the amount of 
time (the "time of flight" or TOF) required for the ion to hit a detector (Figure 
3). This allows the molecular weight or mass of a single positively charged 
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molecule to be accurately measured and displayed according to their mass: 
charge ratio (m/z).85 
Figure 3. MALDI-Tof mass spectrometer 
Protein Identification 
 
 
Cutting individual spots from the gels can identify proteins that are 
separated on 2-DE gels. The excised protein spot is digested with trypsin and 
separated into specific amino acid sequences and broke down into a mixture 
of peptides. The peptide fragments produced by trypsin digestion of any 
protein have a unique mass that can be measured accurately with MS to 
produce a peptide mass "fingerprint". This protein signature or fingerprint is 
then compared with the peptide masses predicted from theoretical digestion of 
protein sequences contained within published databases such as SWISS-
PROT,86 thus allowing identification of the protein from which the fragments 
originated.87 Its high sensitivity and the possibility of analysis of complex 
mixtures have made this technique a method in common use in the 
characterization of peptides isolated by electrophoresis or chromatography. 
Mass spectrometry has proved to be effective not only in the identification of 
proteins but also in the determination of post-translational modifications, and 
more recently also in the context of relative quantification via labeling of 
proteins. 
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Complementary technologies have been developed able to apply the 
high sensitivity and specificity of MS to rapid and direct mapping and 
imaging of biomolecules that are present in body fluids or tissue sections. The 
available techniques, SELDI-TOF MS (surface-enhanced laser desorption 
ionization time of flight mass spectrometry) and MALDI-TOF MS (matrix-
assisted laser desorption ionization time of flight mass spectrometry), use a 
laser to desorb and ionize proteins from a solid surface and thus are called 
"laser desorption" techniques. MALDI-TOF MS does not require 
solubilization or pre-separation of tissue samples. Using this technique, high 
resolution mass spectrograms can be obtained directly from solid phase 
samples (e.g., in tissue sections).88,89 In a typical procedure, a 12-micron 
frozen tissue section is freeze-dried onto a conductive MALDI plate, and 
coated with a solution of a matrix, usually a low molecular weight crystalline 
compound such as a cinnamic acid analog. When dry, the sample is 
introduced into the vacuum inlet of a mass spectrometer, and then irradiated 
with a finely focused laser beam from a 377 nm N2 laser. The beam, which is 
approximately circular with a diameter of 25 microns, is directed at regions of 
interest in the tumor, which are selected by examining adjacent tissue sections 
that are processed for conventional light microscopy (hematoxylin and eosin, 
HE). Each consecutive spot produces a mass spectrum that reflects the 
molecules that are present within the irradiated area. For most tissue sections, 
over 200 protein and peptide peaks are found in the mass spectrum from each 
spot ablated by the laser. Application of the laser, acquisition of data, 
download to a computer, data processing, and repositioning of the sample 
stage are all automated, and the procedure is rapid. Samples can be obtained 
from well-defined regions (e.g., normal tissue, malignant tissue, necrotic 
areas, the leading edge of a tumor), many of which have unique subsets of 
proteins and peptides. Images can then be created of different patterns of 
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protein expression by integrating the peak areas and plotting the relative 
values using a color scale (Figure 4). 
Figure 4. Representative matrix-assisted laser desorption ionization time-of flight mass spectrography 
(MALDI-TOF MS) protein spectrum obtained directly from human lung tumor tissue 
  
 
MALDI-TOF MS is used to generate protein profiles in both linear and 
reflector modes, with subsequent MALDI-TOF MS to identify low molecular 
weight serum peptides in the protein profile with high spectral resolution.90 
On the other hand, due to the presence of matrix ions, one of the limits of this 
procedure is the loss of sensitivity in the higher region of the protein size.  
Mainly for the conventional proteomic procedures the following step is 
often represented by the analysis through a so called “validation technique”, 
which aims to verify the real over- or under-expression of a particular protein 
through universally accepted methodologies like western blotting, 
immunohistochemistry and/or tissue microarray immunohistochemistry. 
Nonetheless very recently, direct quantification techniques has been 
successfully proposed.91 
Concerning the possible application of molecular technologies to 
clinical oncology, it has to be considered that despite significant progress in 
the field of DNA microarrays and gene expression profile, there are some 
limitations in using a genomic (nucleic acid) approach to molecular tumor 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 39 - 
classification. This is the reason of the growing interest on proteomics. In fact 
proteins rather than nucleic acids represent the functional output of the cell 
and RNA expression is often not tightly correlated with protein expression.92 
Moreover genomic analysis does not detect posttranslational changes 
such as proteolytic processing, phosphorylation or glycosylation, which can 
alter the activity of a protein. These posttranslational modifications are often 
critical in various signaling pathways involved in tumorigenesis.93 
Compared to the study of DNA or RNA expression patterns, analysis of 
protein expression may provide a more accurate understanding of the 
molecular complexities of human tumors.94 
Preliminary reports of the analysis of protein expression profiles in 
oncologic patients using 2-DE could describe only differences in patterns of 
protein expression rather than specific proteins.95 Separated proteins could 
only be identified by co-migration, specific antibody labeling, or chemical 
microsequencing, all of which were time-consuming and technically 
demanding. Because there are no simple methods for protein amplification, 
highly sensitive methodologies needed to be developed to identify low-
abundance proteins that are important in the malignant process. Although 2-
DE is a powerful tool for the study of differences in protein expression that 
characterize cell types or tissues, it is difficult to apply this technique to large 
numbers of clinical samples.96 The number of unique proteins contained in a 
tumor is higher than the number of spots detectable with 2-DE. Moreover the 
study of lysates from cell lines and human tissues with the aim of identifying 
"tumor-specific" changes in protein expression is limited by the heterogeneity 
of human tumors, the inclusion of stromal, normal cells, and premalignant 
lesions along with tumor in many samples.  
The result of a proteomic analysis is therefore the correlation of 
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changes in protein expression with a given phenotype. Once a protein (or 
biomarker) "signature profile" has been identified, results must be validated in 
independent, large study sets. This requires high throughput technology, 
consenting the analysis of hundreds of cancer tissue samples at a time. The 
identified proteins may represent important biomarkers for early diagnosis, 
yield valuable information about the disease process and represent targets for 
novel therapeutic intervention, or even provide surrogate markers for 
therapeutic efficacy or treatment-related toxicity. Preliminary data suggest 
that MALDI-TOF MS analysis of protein expression profiles from frozen 
sections of human surgically resected lung tumors (non-small cell lung 
cancers, NSCLC) allows the separation of tumors according to histologic 
type, providing potentially useful prognostic information.97,98 
In one of the preliminary reports of proteomics’ application to clinical 
oncology, protein spectra were obtained from 79 lung tumors and 14 normal 
lung tissues. A model was established using 42 lung tumors and eight normal 
samples, which was then validated on a blinded test cohort of 37 lung tumors 
and six normal lung samples. Using this approach over 1000 distinct protein 
species could be analyzed from less than one nanogram of each tissue sample. 
The protein spectra of lung cancers and normal lung resulted different with 
peaks in the tumor samples higher than in normal lung, and clearly 
distinguishable from background noise. A discriminatory pattern of protein 
expression was also demonstrated when lung adenocarcinoma and squamous 
cell carcinoma were compared and when lung primary tumors were compared 
to pulmonary metastasis. These proteomics results were shown having 
prognostic value as well generating 15 distinct MS peaks that could 
distinguish between patients with good or poor prognoses. This association 
was present even after adjustment for stage and histologic grade. 97  
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A commercially available serum proteomic MALDI-TOF based 
classifier (VeriStrat) was adopted for stratifying and predicting survival after 
treatment with erlotinib in a blinded fashion to pretreatment sera from 
recurrent advanced NSCLC patients. VeriStrat was found to be able to 
classify these patients into two significantly different outcome groups that had 
“better” and “worse” outcomes.99  
Proteomics demonstrated a good clinical-scientific impact also in 
urologic oncology. In fact the well demonstrated lack of specificity of serum 
PSA for discriminating between prostate cancer and benign prostatic 
hyperplasia (BPH) limits its utility for early diagnosis. Several reports already 
suggested that serum proteomics might provide a better biomarker for early 
detection of prostate cancer.100 
One of the first studies that used a serum SELDI MS to analyze serum 
proteins and differentiate prostate cancer from generated a serum protein 
profiles that allowed developing a decision tree classification algorithm, 
which correctly classified 96% of the samples. In a subsequent blinded 
validation set, this approach still showed 83% sensitivity and 97% of 
specificity.101 
In hematology a study from peripheral blood samples of 57 adults with 
a confirmed diagnosis of acute lymphoblastic leukemia could successfully 
provide a decision tree based on proteomics providing a predictive value of 84 
to 92 percent. Interestingly recurrence prediction was independent of 
cytogenetics, marrow blast count, and serum level of lactate dehydrogenase, 
beta-2 microglobulin or surface marker studies.102  
Potential biomarkers have been identified by proteomics in many other 
cancers so far: Olsen and coll. recently demonstrated that antigens expression 
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profile of breast cancers could represent potentially a high specific 
biomarker;103 in ovarian cancers MALDI imaging mass spectrometry 
identified a protein (PA28 or Reg-alpha) whose specific antibody could be 
used to discriminate the borderline tumor cases.104  
As for endocrine tumors and disease, the application of 2D-DIGE has 
been successfully demonstrated in several studies on thyroid tumors. Despite 
the tremendous effort that have been made in deciphering alterations in gene 
and protein expression pattern of cold thyroid nodules, the ultimate link to the 
clonal molecular offspring of a cold thyroid nodule is far from being 
understood. Nonetheless some different expression between papillary thyroid 
carcinomas (PTC) and normal thyroid tissue has been already found. Of all 
overexpressed proteins in PTC, the protein S100A6 displayed the highest 
volume ratio between PTC and normal thyroid (6.5-fold). This protein was 
also used for validation of the proteomic approach by immunohistochemistry 
on independent samples of benign and malignant tumors reaching 85% 
sensitivity and 69% specificity for the discrimination between benign and 
malignant thyroid neoplasms.105  
Interesting data have been obtained also by proteomic analysis of 
pituitary adenomas: Ribeiro de Oliveira and coll. studied a series of 20 
secreting and non-secreting pituitary adenomas comparing their protein 
profile with normal pituitary tissue. Between the differently expressed 
proteins (many of them never disclosed before), particular attention was given 
to proteins possibly involved in the pathogenesis of the pituitary adenomas 
(HSP110, B2 bradykinin receptor, CSK and annexin II): all the data but one 
(CSK) were confirmed by western blotting being HSP110 significantly 
overexpressed in prolactinomas and non functioning pituitary adenomas, B2 
bradykinin receptor significantly overexpressed in prolactinomas and annexin 
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II significantly under-expressed in somatotrophinomas.106 
As for adrenal adenomas and carcinomas, although many molecular 
studies addressed to describe genome and transcriptome profiling of these 
tumors have already been published with noteworthy results, few data are 
available at present on adrenocortical tumors proteomic profile.107,108,109 Very 
recently Kjellin and coll. compared the microsomal protein composition of 
eight malignant and six benign adrenocortical tumors with proteomic 
methods. The IGF2 increased level in ACCs confirmed previous microarray 
studies. On the other hand some enzyme and proteins belonging to 
mitochondrial respiration chain and involved in tumor metabolism, showed 
different expression between malignant and benign/normal adrenal tissue. 
This may indicate a shift in energy metabolism where glycolysis may be 
favored (Warburg effect).110 One of these proteins (GRIM-19, Tumor 
Suppressive Protein Gene Associated with Retinoid-Interferon-Induced 
Mortality), under expressed in ACCs, has already been identified in other 
malignancies and seems to be able to interact with STAT3 with regulatory 
role, as suggested by Li and coll.111 Moreover other authors have also 
reviewed the role of GRIM-19 in cancer development: some of these studies 
could demonstrate an involvement of GRIM-19 also in endocrine tumors 
(e.g., Hurtle cells thyroid adenomas).112,113 
Although performed on cell lines lysate and not on fresh human tissues, 
another piece of the puzzling proteomic profile of adrenal tumors have been 
found by Stigliano and coll.: the authors showed that mitotane (the unique 
adjuvant therapy in adrenal cancer available to date) could affect proteome in 
an adrenal malignant tumor cell line. The data allowed identifying some 
classes of proteins involved in energetic metabolism, stress reaction, 
cytoskeleton structure and tumorigenesis.114 
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AIM OF THE STUDY 
 
The main purpose of this study is to improve the diagnostic process of 
malignant and benign adrenal tumors trying to provide the pathologist with a 
morphometric valuable and reliable model that could be easily integrated into 
the present diagnostic algorithm of the disease. We decided to develop a 
computer vision method for IHC analysis and to compare the method to 
visual interpretation of IHC staining. A highly studied biomarker (Ki-67) with 
known prognostic value in many cancers (also adrenal cancer) was chosen as 
target. In this study, a tool for semi-automated quantitative assessment of Ki-
67 expression is presented. The IHC quantification method was evaluated by 
comparing the results with visual assessment of Ki-67 expression in a 
comprehensive series of adrenocortical adenoma and carcinoma specimens. 
Moreover the same morphometric model was applied also for the 
quantification of reticulin staining and inflammatory infiltration.  
The secondary aim of this study was the individuation of sensitive 
biomarkers with a possible diagnostic and prognostic role: 
immunohistochemistry and proteomics evaluation should consent the 
individuation of different subtypes of benign and malignant lesions 
contributing to a better characterization of pathogenic mechanisms and 
disease progression. The identification of novel biological markers suggestive 
of malignancy would afford an earlier diagnosis of ACCs and the 
development of potential target therapies would lead to increased likelihood 
of long-term survival for the patients affected. A better definition of peculiar 
subtypes of adrenal lesions would also allow an earlier identification of silent 
benign tumors with secreting attitude before any irreversible metabolic 
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damage would be established, with a significant impact also on healthcare 
costs.  
Eventually data obtained by morphometry and proteomic signature of 
ACCs and ACAs could be integrated in future with clinical-surgical-
radiological and histological data trying to explain the inconsistencies often 
found among the histological data and the clinical course of the disease and 
possibly providing an accurate prognostic stratification of these 
heterogeneous tumors.  
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METHODS 
 
Morphometric Model 
 
In this study, we examined retrospectively 11 ACA (median size= 6.2 
cm, range 5-16 cm) and 18 ACC (median size= 11 cm, range 4-19 cm). 
Specimens were obtained from the archival files of 29 patients (9M/20F) 
submitted to adrenal surgery at the Division of Minimally Invasive and 
Oncological Surgery, Niguarda Hospital in Milan (Table 4). All patients were 
followed at the Department of Endocrinology at the same hospital. For all 
samples (for morphometric model and also for proteomic study, see below) 
informed consent of the patient was obtained after the approval of the 
Hospital Ethical Committee. 
Table 4. Characteristics of patients. 
Lesion Dimensions (cm) Age M/F 
ACA 4-11 28-59 4/7 
ACC 5-19 25-68 5/13 
  
ACAs and ACCs were defined grossly and microscopically following 
the criteria and the nomenclature system of pathologic features proposed by 
Weiss et al. (see above). All primary malignant tumors reviewed as part of 
this study demonstrated three or more of the histologic criteria needed for the 
diagnosis of ACC as defined by Weiss score. 
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Two experienced pathologists without the pathologist’s knowledge of 
the patients’ clinical characteristics or outcomes reviewed all specimens.  
In all cases investigated, 2-cm3 blocks were obtained, then immediately 
formalin fixed soon after the receipt of the adrenal specimen and embedded in 
paraffin. For each case, three consecutive sections 4 µm thick were obtained 
from the corresponding block.  
Each section series was stained with different methods (see Figure 5):  
- Hematoxylin-Eosin (HE) to confirm the diagnosis of adrenal nodular 
lesions. 
-  Monoclonal antibodies against Ki67 (Rabbit anti-human ki-67 
monoclonal Ab Clone SP6, 1:400 - Thermo Fisher Scientific, CA - 
USA) to assess volume fractions of KI67 negative and positive cells 
(nuclei and cytoplasm), nucleus\cytoplasm (N\C) ratio both for 
marked/unmarked cells 
- Monoclonal antibodies against CD8 (mouse monoclonal anti-CD8 
1:100, Abcam-USA), a two chain glycoprotein that is expressed on the 
surface of circulating T-cells. 
- Monoclonal antibodies against CD15 (Mouse monoclonal anti-CD15 
clone G10F5, BD Pharmingen™-USA), a glycosyl-phosphatidyl-
inositol linked protein expressed on granulocytes.115 
-  Silver impregnation for reticulin fibers using the Gordon and Sweets 
method to assess the cell plate architecture.116 
- Blood and lymphatic vessels were also identified. 
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!
Figure 5. Material and Methods: Hematoxylin-Eosin (HE, a, 10x), 
immunostaining for Ki-67 (b, 40x), CD15 (c, 40x), reticulin (d, 10x) 
a !b 
!c d 
 
The variables assessed by morphometry are listed in Table 5 and 
include cellular compartment, fibrous stromal, and vascular supply in both 
groups of lesions. 
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Table 5. Morphometric model. 
Ki-67 (40x magnification): Volume fractions referred to the entire tissue occupied by 
nuclei of Ki-67 negative cells (Vvnucneg) 
cytoplasm of Ki-67 negative cells (Vvcytneg) 
nuclei of Ki-67 positive cells (Vvnucpos) 
cytoplasm of Ki-67 positive cells (Vvcytpos) 
ratio nuclei/cytoplasm of Ki-67 negative cells (N/Cneg) 
ratio nuclei/cytoplasm of Ki-67 positive cells (N/Cpos) 
other structure (vessels and inflammatory infiltrate) (Vvother) 
Inflammatory infiltration (40x): Volume fractions referred to the entire tissue occupied by 
T lymphocytes (VvCD8) 
Granulocytes  (VvCD15)  
Reticulin (10x): surface fraction (surface in unit volume) of reticulin 
Reticulin (Svret) 
  
During the analysis of the data we decided also to create a secondary 
category of cell volume fraction (see results): Vvcellpos, meaning the Volume 
fraction of Ki-67 cells positive referred only to cell tumor compartment 
(vessels and blood cells excluded). 
The morphometric analysis was performed at two magnification levels 
using an interactive approach with a high-resolution computerized image 
analyzer (Kontron-Zeiss KS 400) that included a color video camera (JVC 
TK-C1381EG) attached to a light microscope equipped with a motorized 
stage with 10X and 40 X objectives and auto-focusing software. The software 
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system, tailored on the research needs of our team, consisted of different 
programs to control interactively the scanning stage and autofocus functions.  
The analysis works as follows: images are acquired by the video 
camera and displayed on the monitor. The analyzer automatically 
superimposes to each microscopic field different grids of points and lines, 
included in a test area 504 x 504 pixels, allowing an evaluation of the 
stereological variables.117 
The observer can interactively apply techniques of enhancement for a 
better definition of the different structures. It is also possible to exclude fields 
in which the tissue section may not be suitable for analysis due to technical 
artifact. An algorithm automatically controls the scanning stage operation in 
order to avoid duplicate measurements of the same structures. 
Two different grids have been used: a 144-points square lattice to 
evaluate the volume fractions of the components investigated and a 4-lines 
grid to evaluate reticulin surface (Figure 6a and 6b). To examine the 
microscopic fields, two objectives 10X and 40 X have been used. 
Figure 6. a) 144-points square lattice to evaluate the volume fractions of the cellular compartment of 
the tumors, b) a 4-lines grid to evaluate reticulin surface in the tumors. 
 
a)       b) 
  
 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 51 - 
 
On stained sections at 10X magnification surface area of reticulin was 
evaluated by superimposing on each microscopic field displayed on the 
monitor a grid of lines: surface densities were calculated by differential 
intersection counting. The grid was then rotated by 45°, 90°, and 135° and 
counts repeated each time. On stained slices at 40X, volumetric analysis of 
Ki-67 negative and Ki-67 positive cells was performed by differential point 
counting118 and more than 250 microscopic fields systematically selected 
were examined. During point counting procedure, a single experienced 
operator blinded to pathologist’s diagnosis or clinical history identified the 
different structures.  
Ki-67 assessment by morphometry was compared with the histological 
semi-quantitative scoring by regression analysis. 
Lastly, to assess the reproducibility of our morphometric model, 10 
specimens were randomly selected from the entire pool of specimens, 
reassessed as above by another blinded operator and compared to the initial 
counting.  
Statistical Analysis: SPSS 21.0 software were used for statistical 
analysis. For each parameter, a comparison between the two groups of lesions 
has been performed by variance analysis. Statistical significance was 
established at the p<0.05. Furthermore, regression analysis was used to test 
reproducibility of the morphometric analysis, according to the results obtained 
by two blinded operators. 
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Proteomic Expression Analysis 
 
The 2D fluorescence differential gel electrophoresis (DIGE) technique 
represents to date the most sophisticated and straightforward approach to 
discovering protein patterns that distinguish disease and disease-free states 
with high sensitivity and specificity. In a DIGE system, experimental and 
control samples and an internal standard (consisting of equal protein amounts 
of all samples) are labeled with spectrally resolvable fluorescent dyes before 
isoelectric focusing. Subsequently, the pre-labeled samples are resolved 
within the same analytical 2D gel run. The multiplexing of different samples 
allows the direct quantitative measurement of experimental and control 
samples co-migrating within one 2D gel. In addition, the normalization of all 
2D images to the common 2D image of the internal standard permits inter- 
and intragel matching as well as the normalization of spot volumes across 
different gels. Thus, each spot has its own standard, which allows the direct 
quantitative measurement of the differentially labeled experimental and 
control sample and the equivalent protein signal from the standard. The 
sensitivity of commercially available fluorescent dyes is comparable to that of 
silver stain. Furthermore, because of its high linearity and wide dynamic 
range, the use of CyDyes is a valuable tool for quantitative proteomics.118,119 
More in detail:  
Sample preparation 
Frozen tissue samples from 7 ACCs, 5 ACAs and 5 normal adrenal 
glands (surgically removed for other non influencing-contaminating disease) 
with were grounded by mortar and pestle in dry ice, and an aliquot of each 
sample powder was solubilized in lyses buffer containing: 30 mM Tris-HCl 
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pH 8.5, 7 M Urea, 2 M Thiourea, 4% CHAPS , 0.1% Triton X100 and 
protease inhibitor.  In order to remove contaminants, lipids, salts, detergents 
and other non IEF compatible reagent, sample extracts were treated by 2D 
clean-up kit  (GE Healthcare). The proteins were than re-suspended in lyses 
buffer and protein concentrations were determined using 2D Quant Kit (GE 
Healthcare). 
2D-DIGE 
First of all we have to consider that Two Dimensional Gel 
Electrophoresis (2D-DIGE) is a modification of 2-DE technique in which 
protein samples, labeled with different fluorescent dyes, are separated in the 
first dimension according to their isoelectric point and in the second 
dimension by their molecular mass.   
The gels obtained were scanned with excitation wavelength of each dye 
and detected using fluorescent imaging scanner. Protein minimal labeling 
reactions were performed: 50 µg of protein extract from each sample, were 
labeled with 400 pmol of Cy5 dye (CyDye, GE Healthcare), while an internal 
standard, generated by pooling an aliquot of all sample protein extracts, was 
labeled with Cy3 dye according to manufacture’s recommendations. For each 
2D-DIGE gel, 50 µg of a Cy5-labled sample and 50 µg of a Cy3-labled pool 
were mixed and the final volume brought up to 250 µL with rehydration 
buffer (7 M urea/2 M thiourea/4% CHAPS/40 mM Tris- HCl, pH 8.8) 
containing 1% IPGphor ampholytes, pI range 3-10 (GE Healthcare), 30 mM 
dithiothreitol (DTT) and a trace of bromophenol blue. 24 cm IPG DryStrip pH 
3-10 non linear gradient (GE Healthcare) were rehydrated and focused on an 
Ettan IPGphor II (GE Healthcare) using the following protocol: 6h at 30 V, 6h 
at 60V, 2h at 200V, 2h at 500V, 2h at 1000 V, 1.5h at 2000V, 1.5h at 3000V, 
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4h gradient 3000-8000V, 5h at 8000V. The next day, DryStrips were placed 
at −80 °C.  
DryStrips were thawed at RT for 15 min, equilibrated in SDS-sample 
buffer (6 M urea, 75 mM Tris-HCL, pH 8.8, 20% glycerol, 2% SDS, 65 mM 
DTT) for 15 min and then for 8 min in SDS-sample buffer containing freshly 
added iodoacetamide (135 mM). Each strip was then placed on top of a 12% 
constant polyacrylamide SDS-PAGE gel. Second-dimension separation for all 
gels was carried out in Ettan Dalt separation unit (GE Healthcare) overnight at 
20°C, until bromophenol blue reached the bottom of the gel. 
After electrophoretic separation, CyDy labeled gels were scanned on a 
Typhoon imager 9200 (GE Healthcare) using the specific laser band-pass 
filters for each dye’s excitation and emission wavelengths, generating 
overlaid multi-channel images for each gel. Each gel was scanned 
individually and Photo Multiplier Tube (PMT) voltages were adjusted for 
maximum image quality with minimal signal saturation and clipping. Images 
were cropped and exported as 16-bit GEL files using ImageQuant TL (GE 
Healthcare) and imported into SameSpot Progenesis (Non Linear Dynamics). 
Images and statistical analysis 
All images are loaded in the analysis software, which automatically 
detects and matches spots and normalizes signals using the info contained on 
the internal standard, which is identical on every gels prepared. The internal 
standard is a balanced mix of all samples included in the experiment and it 
allows the representation of all spots present in samples also in the reference. 
Only proteins with spot volumes consistently different in all replicates will be 
considered differentially expressed. Statistical analysis was performed using 
traditional paired or non-paired T-test or Anova's to calculate p-Value 
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associated with distribution of spots signal across groups of samples to be 
compared. Other type of supervised and non-supervised classification 
methods can be applied with PCA, hierarchical clustering, and single decision 
tree. 
Protein identification by Mass Spectrometry 
Protein spots, selected by statistical analysis, were automatically picked 
from preparative gels by Ettan Spot Picker (GE Healthcare) and transferred to 
96-well plates. Spots were destained in 50% methanol/50 mM ammonium 
bicarbonate and incubated with 30 mL of 4 ng/mL trypsin (Promega) 
dissolved in 10 mM ammonium bicarbonate for 16 h at 371C. Released 
peptides were subjected to reverse-phase chromatography (Zip-Tip C18 
micro, Millipore), eluted with 50% ACN/1% formic acid. Briefly, 1 mL of 
peptides mixture was spotted onto the sample plate of an Ultraflex III 
MALDI-ToF/ToF (Bruker Daltonics) mass spectrometer; an equal volume of 
10 mg/ mL CHCA matrix dissolved in 70% ACN/30% 50 mM citric acid was 
applied and spots were air dried at room temperature. MS proceeded at an 
accelerating voltage of 25 kV and spectra were externally calibrated using 
Peptide Calibration Standard mixture (Bruker Daltonics); 1000 laser shots 
were taken per spectrum. Proteins were identified by comparing the digest 
peaks with a computer-generated database of tryptic peptides from known 
proteins using MASCOT, which utilizes a robust probabilistic scoring 
algorithm. Search was carried out by correlation of uninterpreted spectra to 
Homo sapiens entries in NCBI Data-base. With regard to MASCOT 
parameters, one missed cleavage per peptide was allowed and 
carbamidomethylation, as fixed modification, and methionine oxidation, as 
variable modification, were set. Peptide mass tolerance was set at 30ppm. 
Proteins were identified by searches of a mammalian subset of the SWISS-
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PROT and TrEMBL databases.  
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RESULTS 
 
Morphometric model: 
Results of the morphometric study are shown in Tables 6-9 and in 
Figures 7–10.  
On Ki-67 stained sections, the volume fraction of nuclei in unit volume 
showed highest values in ACC both in Ki-67 negative cells (ACC .12046, 
ACA .06637) and in Ki-67 positive cells (ACC .01227, ACA .00104). 
The volume fraction of Ki-67 negative cells was highest in ACA (ACC 
.71031, ACA .78537); on the contrary, the volume fraction of Ki-67 positive 
cells was highest in ACC (ACC .02988, ACA .00503).  
When considering N/C ratio, ACC showed the highest values in both 
Ki-67 negative cells (ACC .20535, ACA .09260) and Ki-67 positive cells 
(ACC .68022, ACA .27281).  
The volume fractions of the other compartments of the lesion (vascular 
structures, inflammatory infiltrate) were higher in ACC (ACC .25969, ACA 
.20963). 
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Table 6. Morphometric variables evaulated by Ki-67 immunostaining for the different lesions 
(mean±standard deviation; degrees of freedom 1; 27) 
 
Variables Dimension ACA ACC p F 
Vvnucneg  mm3/mm3 .06637±.0153 .12046±.0226 <.0001 45.718 
Vvcytneg mm3/mm3 .71900±.0295 .58985±.0571 <.0001 52.973 
Vvnucpos mm3/mm3 .00104±.0004 .01227±.0088 <.0001 20.656 
Vvcytpos mm3/mm3 .00399±.0011 .01771±.0094 <.0001 26.409 
Vvcelneg mm3/mm3 .78537±.0304 .71031±.0656 <.001 15.209 
Vvcelpos mm3/mm3 .00503±.0013 .02988±.0186 <.0001 24.304 
Vvother mm3/mm3 .20963±.0299 .25969±.0155 <.05 6.366 
Vvcellpos* mm3/mm3 .00639±.0017 .04039±.0245 <.0001 20.82 
N/C neg  .09260±.0228 .20535±.0396 <.0001 69.151 
N/C pos  .27281±.1449 .68022±.1693 <.0001 44.493 
 
Volume fractions referred to the entire lesion in the test area = 504x504 pixels occupied by nuclei and 
cytoplasm respectively in Ki-67 cells negative (Vvnucneg and Vvcytneg) and Ki-67 cells positive (Vvnucpos 
and Vvcytpos), vascular and inflammatory infiltrate (Vvother), Ki-67 cells negative and positive (Vvcelneg 
and Vvcelpos); N/C represents the nuclei/cytoplasm ratio in both type of cells. 
*Vvcellpos: Volume fraction of Ki-67 cells positive referred to cellular compartment.  
The volume fractions of inflammatory infiltration were higher in ACCs 
than in ACAs (CD15: ACC .00312, ACA .00098; CD8: ACC .01070, ACA 
.00356). The surface fraction of reticulin was significantly lower in ACC 
(SvRet: ACC 10.43, ACA 37.24).  
Table 7. Morphometric variables evaluated by CD15/CD18 and reticulin immunostaining for the 
different lesions (mean±standard deviation; degrees of freedom 1; 27) 
Marker Dimensions ACA ACC p F 
VvCD15 mm3/mm3 .00098±.0004 .00312±.0007 <.0001 60.231 
VvCD8 mm3/mm3 .00356±.0012 .01070±.0094 .068 3.802 
Svret mm2/mm3 37.24±9.29 10.43±5.89 <.0001 60.019 
 
Volume fractions occupied by CD15 granulocytes (VvCD15), CD8 T-lymphocytes (VvCD8), and surface 
fraction occupied by reticulin (SvRet).  
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Figure 7. Volume fractions of nuclei and cytoplasm respectively in Ki-67 negative cells (Panel A) and 
Ki-67 positive cells (Panel B), in both lesions. 
Panel A      Panel B 
  
Figure 8. Linear regression of pathologist assessment of the percentage of Ki-67 positive cells on the 
morphometric evaluation. When comparing morphometric analysis to pathologist’s scores, the data of 
the point grid analysis revealed significantly lower values with respect to conventional histopathology, 
as shown by the regression line. 
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Figure 9. Surface fraction of reticulin for each lesion investigated 
  
Figure 10. Volume fractions of CD15 and CD8 positive cells for both lesions 
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Table 8. Statistical analysis of inter-observer agreement on morphometric analysis: 10 randomly 
selected specimens are compared with initial point counting and with differential intersection 
counting. F represents the variance ratio related to the source of error for each evaluation by the two 
operators. 
 
 Vvnuc neg Vvcyt neg Vvnuc pos Vvcyt pos Vvoth CD15 CD8 Svret 
F 0.654 0.587 0.102 0.447 0.091 0.895 0.065 0.754 
p 0.321 0.654 0.729 0.573 0.528 0.367 0.619 0.301 
   
 
Finally we also evaluated the prognostic value of new ENSAT staging 
classification in the same series of ACCs comparing our findings to tumor 
Weiss score and ki-67 expression (both from pathologist visual evaluation 
and morphometric approach), with regard to the disease-free and disease-
specific survival. Clinical and pathological data of the 18 pts affected by 
ACCs (14F, 4M, median age 52 yrs, range 25-78) surgically treated, were 
retrospectively reviewed; the follow up period was 26 months (median, range 
6-192). ACC staging was performed accordingly to ENSAT classification; 
tumor malignancy was assessed accordingly to Weiss system. A multivariate 
analysis of disease-free and overall survival in ACC according to Weiss score 
and ki-67 was performed.  
The 70% of tumors were hypersecreting; mean size was 10,7cm (range 
50-2500), mean weight was 512g (range 50-2500). In our series the visual 
evaluation of the pathologist led to consider a Ki-67 greater than 7% 
(sensitivity 85,7%, specificity 62,5%, ROC analysis) and Weiss score>4 
(sensitivity 100%, specificity 50%) were the best cut-off values suggestive for 
a poor prognosis (Kaplan-Meyer, p=0,06 and p=0,04 respectively). Taken 
together the two risk factors showed a significant effect on survival 
probability (Cox-regression, p= 0,04). Ki67>7% and Weiss score>4 showed a 
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slight correlation also with disease-free survival (Kaplan-Meyer, p=0,06 and 
p=0,04 respectively); when both risk factors were concomitantly present, the 
correlation with probability of disease recurrence was higher (Cox-regression, 
p=0,02).  
When we applied our morphometric model, the Ki-67 cutoff value 
decreased to 1,2% with a sensitivity of 94% and a specificity of 100% 
maintaining the same significant correlation with the disease outcome. 
Proteomics expression study: 
After adequate selection of the protein spots obtained by DIGE, taking 
into account also some technical pitfalls (e.g. some of the spots was not 
removable from the gel, the total amount of some proteins was not enough to 
perform the following step, the MS) we could detect 30 spots with significant 
differential expression in ACCs versus ACAs and 45 protein spots differently 
expressed between ACCs and normal adrenal tissue. Many of these proteins 
have been also identified by mass spectrometry; some of them are still on 
study. As for the interpretation of the results, in the analysis of this database 
we decided arbitrarily to select only the proteins with relevant possible role 
involved in tumorigenesis, tumor metabolism and/or aggressiveness to 
proceed with the validation step (now ongoing). We focused our attention on 
the proteins with the higher fold variation.  
In ACCs the 62% of differentially expressed proteins resulted 
overexpressed with respect to ACAs: among them vimentin (accession nr 
P08670) and vitamin D-binding protein (DBP, accession nr P04276) resulted 
the most varied (3.2 and 3-fold more expressed in ACCs than in ACAs 
respectively). On the other hand the remaining 38% of proteins resulted 
under-expressed in ACCs with regard to ACAs, being cathepsin D (CD, 
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accession nr P07339) and aldose reductase (AR, accession nr P15121) both 3-
fold less expressed in ACCs than in ACAs.  
We could find similar differences once we compared normal adrenal 
tissue to ACC protein expression profile (62% of the 35 differential protein 
spots resulted overexpressed in ACCs), also considering the same proteins 
described above, although with slight modifications in terms of fold variation 
(vimentin showed 2.4 fold increase and DBP 1.6 fold increase, CD showed 
1.8 fold decrease and AR 2.4 fold decrease, in ACCs with regard to normal 
adrenal tissue). Considering the purpose of the study, the more remarkable 
additional protein we could demonstrate to be overexpressed in ACCs versus 
normal adrenal tissue (1.8 fold increase) and not present in ACAs vs ACCS 
protein expression study, was lactate dehydrogenase (LDH, chain A accession 
nr P00338). 
Table 9 and Table 10 summarize the proteins detected so far, and their 
fold variation. 
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DISCUSSION 
 
Several histologic features have been considered in the differential 
diagnosis between malignant and benign adrenocortical lesion.38,40,121,122 
Adrenocortical cancers are mainly characterized by high mitotic index, high 
nuclear grade and disruption of the normal adrenal architecture. However, no 
single histological criterion can certainly define the malignancy of the 
adrenocortical lesion. Therefore, several diagnostic algorithms and scoring 
systems have been proposed, including different items of histological 
alteration. However, these scoring systems retain some limitations and the 
morphological differentiation still remains controversial especially in small 
size and purely localized lesions. Moreover, histology-based diagnosis may 
also suffer of the subjectivity of the individual morphological observations. In 
this more “technical” part of the study, we used a computerized morphometric 
approach to evaluate and quantify the morphological features in ACC and 
ACA. On Ki-67 stained sections, the most intriguing results were related to 
both cellular populations, i.e. Ki-67 negative and positive cells, cells not 
stained and stained with Ki-67 marker respectively.  
ACC showed a significantly higher volume fraction of nuclei in unit 
volume both in Ki-67 negative cells (Vvnucneg) and in Ki-67 positive cells 
(Vvnucpos). The volume fraction of cytoplasm in Ki-67 positive cells was 
highest in ACC (Vvnucpos), while ACA showed the highest volume fraction 
of cytoplasm in Ki-67 negative cells (Vvnucneg). These data reflect the 
different trend of nuclear/cytoplasmic ratio (N/C) between the two groups: 
ACC showed the highest values of N/C in both Ki-67 negative cells and Ki-
67 positive cells, when compared to the corresponding cellular population in 
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ACA. The volume fraction of Ki-67 negative cells (Vvcelneg) was highest in 
ACA; conversely, the volume fraction of Ki-67 positive cells (Vvcelpos) was 
highest in ACC. The volume fractions of the other compartments (vascular 
structures, inflammatory infiltrate) were highest in ACC. 
According to these results, it could be resumed that ACC are 
characterized by increased nuclear and cellular density, which appear as 
“nuclear clouding” in histological specimens.  
Ki-67 has been studied with a morphometric model in several types of 
cancer, some of which are breast, bladder, brain, colon and prostate cancers 
and it is expressed during all phases of the cell cycle, independently of the 
duration of the cell cycle.123,124 Different studies have explored the use of Ki-
67 as cell proliferation marker in the diagnosis of adrenocortical neoplasm. 
Wachenfeld et al. found that a Ki-67 staining index over 5% could be 
considered a good marker for malignancy in adrenocortical neoplasms.121 
Other Authors found a higher Ki-67 index in ACC compared with ACA, but 6 
of 15 ACC examined had a Ki-67 labeling index within the range of 
adenomas.37 These differences could be related to technical pitfalls but could 
also underline that the quantification of Ki-67 in histologic samples represents 
a critical point. Sampling, individual morphological observations subjectivity 
and mainly inter-observer variability could be sources of error in the 
interpretation of some lesions therefore limiting a semi-quantitative grading. 
In this setting, when comparing morphometric analysis with the 
quantification of Ki-67 by pathologist, our results were significantly lower 
with respect to conventional visual histopathology, as shown by the 
regression line in figure 8.   
How can we explain these data?  
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In assessing the amount of Ki-67 positive cells in histological samples, 
pathologists usually try to estimate the proportion of these cells, so measuring 
a cell count fraction instead of a volume fraction. This estimation is not the 
same as measuring by morphometry the total area occupied by Ki-67 positive 
cells, where the results are often given as percentage of histologic sample 
area. Moreover, it must be underlined that pathologists usually count Ki-67 
positive cells in 50 high-power fields (HPF) selecting conventionally the areas 
of greatest concentrations of positively stained cells (named “hot spot 
areas”).  
In our analysis, we have examined more than 250 microscopic high 
power fields at 40X magnification and, to estimate the “total” amount of Ki-
67 positive cells, we have referred volume fractions of Ki-67 positive cells to 
the cellular compartment, i.e. the reference volume (Vvcellpos), as shown in 
Table 6. 
Accordingly to our results, all ACAs showed Ki-67 values < 1% when 
compared to ACCs. We recognize that our method is not completely 
comparable to the pathologist evaluation, certainly for the automated 
approach but also for the rational and the different criteria of selection and 
evaluation of the samples’ areas. On the other hand this method could be 
helpful, for example, for those cases in which a high Ki-67 labeling observed 
in hot spot areas is associated with an otherwise inexplicable favorable 
outcome. There was no overlapping between the two groups apart for one 
case. One ACC case (Weiss score 2, ENS@T III stage due to vein cava 
thrombus) in fact showed low Ki-67 value on both computerized 
morphometric analysis and pathologist’s evaluation (1%) fitting in the range 
of ACAs group. To explain this case we examined the clinical history of the 
patient: she had a favorable outcome despite the staging of the disease (stage 
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III ENS@T, with invasion of the vena cava). Although this is not a clinical 
study, this data could suggest that a low Ki-67 index could be related to a less 
aggressive clinical course of an adrenocortical carcinoma, authorizing to think 
to a possible “intermediate-low aggressive” category of ACC. To better 
investigate this suggestion further larger studies are needed. 
Lastly, the surface fraction of reticulin (Svret) was markedly reduced in 
ACC when compared to ACA (Figure 9). Different Authors have underlined 
that the disruption of reticulin framework could be considered a highly 
sensitive pathologic feature of ACC.32,33 In our series, ACC group showed a 
significant negative relationship between reticulin and volume fraction of Ki-
67 positive cells (preliminary data, not shown): therefore we could argue that 
a tumor that scores high for Ki-67 is made of cells that are rapidly dividing 
and growing and it is associated to a progressive decrease and/or 
fragmentation of the reticulin framework.  
Certainly, adding a morphometric semi-automated tool to the classical 
diagnostic algorithm of ACCs means introducing numerical values and not 
only semi-quantitative categories that, in future studies, may actually help in 
identifying subpopulations of adrenocortical tumors depending on their 
morphometric characteristics. As a matter of fact, figure 9 shows that one 
ACC had a surface fraction of reticulin well away, i.e. more than 3 times the 
75-25 interquartile distance from the rest of the tumors. This, in our opinion, 
proves that morphometry can indeed identify also outliers, otherwise covert, 
within a certain cell population. 
To evaluate the reproducibility of our method, 10 randomly selected 
specimens were analyzed by another operator and compared with the results 
of the initial counting. We found (Table 8) a high inter-observer agreement 
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between the two independent morphometric evaluations. This is an important 
endpoint of our study: in fact many authors have recently tried to deal with 
one of the most relevant obstacle in the histological analysis of adrenocortical 
neoplasms: the variability due to the observer subjectivity and experience.54 
In other malignancies the data arising from computerized approach to Ki-67 
evaluation and tumor morphologic histological features have already been 
demonstrated accurate, reproducible and effective.76,123,125 Further validation 
studies are requested to demonstrate that the system we used is able to 
produce acceptable digital slides and to give correct diagnostic interpretation. 
This would permit in the future the clinical use of this technology in a manner 
that does not compromise patient care. 
The outcome of patients with ACC is strictly related to the stage of the 
disease, being new ENSAT proposal a valuable tool to improve the power of 
the stage-related prognostic value. Ki67 expression and Weiss score 
combined may play a role of interest; the computerized morphometric 
approach was able to demonstrate an improvement in diagnostic sensitivity 
and specificity, maintaining also a good correlation with the outcome of the 
disease. Nevertheless, Ki-67 evaluation remains only one of the possible 
useful parameters needed for a better prognostic stratification of these rare 
and fatal tumors, being the finding of even more specific biomarkers the next 
endpoint of future studies. 
We performed a proteomic study to identify a series of proteins that are 
differentially expressed ACCs when compared to ACAs and normal adrenal 
tissue. Following the analysis of protein data, we explored the expression of 
some proteins of interest for tumor pathogenesis and/or aggressiveness. The 
proteomic profile has been only recently completed and therefore the data 
about immunohistochemistry and western blotting are not available at the 
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moment of the presentation of this manuscript. This is the reason because we 
could only argue, so far, about hypothesis and interpretation of the data.  
High-resolution two-dimensional gel electrophoresis (2-DE) has been 
the standard tool for expression proteomics since its introduction more than 
30 years ago. Despite various improvements of the 2-DE technique, one of the 
main inherent limitations of this method is the fact that many proteins that are 
expressed at low levels may escape detection. Bioinformatics software made 
2-DE gel analysis much easier, however several challenges remain in order to 
achieve a non-biased, accurate, and reproducible result. Differences in the 
spot positions between gels are major challenging issue in image processing 
because they impede accurate spot matching: we performed a gel image 
alignment and then the software (DeCyder BVA module V. 6.5) aligned other 
spots based on these landmarks. Moreover the relationship between the 
original protein quantity in the sample and the measured spot intensity is 
affected by various intervening factors such as losses during preliminary 
proteomic procedure steps. It is expected that some proteins would have a 
nonlinear relation between concentration and intensity. The quantification of 
proteins has now become very accurate with the introduction of highly 
sensitive fluorescent stains with a wide dynamic range, technology that has 
been very effectively employed in DIGE (differential gel electrophoresis). 
This avoids ambiguities of spot matching as the samples are separated on the 
same gel, and inter-gel comparisons are greatly improved by the common 
internal standard. In addition, the sensitivity is comparable with silver 
staining, but in contrast with it, fluorescent stains are fully MS compatible. In 
our study the DIGE technology easily consented the individuation of protein 
spots differently expressed between ACCs and ACAs and between ACCs and 
normal adrenal tissue: we could detect 30 and 45 protein spots with 
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significant differential expression in ACCs versus ACAs and ACCs versus 
normal adrenal tissue respectively.  
As from the previous disclosure (see results) we studied more deeply 
only part of the proteins resulted differentially expressed in ACCs. Among 
them we selected vimentin, vitamin D-binding protein, cathepsin D, aldose 
reductase and lactate dehydrogenase because of their possible implication in 
tumorigenesis and tumor progression.  
Vimentin is a major constituent of the intermediate filament (IF) family 
of proteins, is ubiquitously expressed in normal mesenchymal cells and is 
known to maintain cellular integrity and provide resistance against stress. 
Increased vimentin expression has been reported in various epithelial cancers 
including prostate cancer, gastrointestinal tumors, CNS tumors, breast cancer, 
malignant melanoma, lung cancer and other types of cancers. Although the 
over-expression of this protein in cancer has been shown to correlate with 
increased tumor growth, invasion and poor prognosis, the role of vimentin in 
cancer progression remains obscure.127 
The tumor microenvironment is a dynamic system, composed by 
various cells including tumor vascular cells, inflammatory cells and 
fibroblasts. As a major and important component in tumor stroma, increasing 
evidence has shown that spindle-shaped cancer-associated fibro-blasts (CAFs) 
are a significant modifier of cancer evolution promoting tumorigenesis, tumor 
invasion and metastasis by stimulating angiogenesis, malignant cell survival, 
epithelial-mesenchymal transition (EMT) and proliferation via direct cell-to-
cell contact or secretion of soluble factors in most digestive solid tumors.128 
The evidence arose by our proteomic study that in ACCs vimentin is 
overexpressed may be a clue that CAFs could have a role also in this 
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malignant endocrine tumor: to our knowledge this is the first time that CAFs 
is designated as a possible player in adrenocortical cancer tumor processes. 
Moreover as we have demonstrated by our morphometric model through 
semi-quantitative assessment of CD15/CD8 immuhistochemical staining, 
neutrophils infiltration seems to be much more present in ACCs than in 
ACAs: this could represent a new starting point to address further studies to 
better describe the ACC microenvironment.   
There is evidence that vitamin D is capable of modulating several 
features of cancer: anti-carcinogenic properties of this hormone include the 
inhibition of cell proliferation, invasion, metastasis and angiogenesis, and the 
induction of apoptosis and differentiation. The main action of vitamin D is led 
through its nuclear receptor. Nonetheless several evidences of vitamin D 
effects not dependent on gene transcription have already been reported. 
Presumably, these effects are mediated by cell surface membrane receptors, 
such as Vitamin D-binding protein. This protein is a multifunctional protein 
found in plasma, ascitic fluid, cerebrospinal fluid, and urine and on the 
surface of many cell types. In plasma, it carries the vitamin D sterols and 
prevents polymerization of actin by binding its monomers. DBP associates 
with membrane-bound immunoglobulin on the surface of B-lymphocytes and 
with IgG Fc receptor on the membranes of T-lymphocytes. DBP has been 
found overexpressed in a proteomic analysis of nipple aspirates fluid of 
women with breast cancer fine: interestingly in the same series Western blot 
analysis of pooled samples of from healthy volunteers versus samples from 
women with breast cancer confirmed the overexpression of vitamin D-binding 
protein in tumor-bearing breasts.129 Furthermore, regarding breast cancer, 
DBP overexpression has been reported in 80% of breast cancers130 and 
significantly at higher concentrations in breast cancers than in normal breast 
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tissue.131 Moreover vitamin D-binding protein is a Gc-globulin (Group-
specific component) and it is known to be the precursor for the principal 
macrophage activating factor (MAF). During inflammation via modification 
of serum Gc protein by stimulated lymphocytes as compared with de novo 
synthesis of lymphokines seems to be an emergency shunt for the host 
defense response in infectious and inflammatory diseases and appears to be 
the major inflammation-primed macrophage activation cascade. This possible 
action of DBP leads one more times to the tumor microenvironment and the 
possible role of inflammatory infiltration in ACCs. Considering that, when 
de-glycosylated, DBP lacks its pro-inflammatory action, it would be 
interesting if further studies could better define the DBP status in neoplastic 
patients tissues and plasma.132 
Unlike the previous proteins, Cathepsin D has been found under-
expressed in ACCs with respect to ACAs. This protein is a member of the 
peptidase A1 family, it has specificity similar to but narrower than that of 
pepsin A. Cathepsin D is the product of a gene whose mutations are involved 
in the pathogenesis of several diseases, including breast cancer and possibly 
Alzheimer disease. In the last decade an increasing number of studies 
demonstrated that enzymatic function of CD is not restricted solely to acidic 
milieu of lysosomes, with important consequences in regulation of apoptosis: 
some models of apoptosis appear to be dependent either on cathepsins or 
caspases, whereas others rely on both caspases and cathepsins for their 
initiation and execution. In addition to CD enzymatic activity, it has been 
shown that apoptosis is also regulated by catalytically inactive mutants of CD 
which suggests that CD interacts with other important molecules influencing 
cell signaling. While some studies reported that CD could directly induce 
apoptosis, some others suggest that CD promotes apoptosis induced by 
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cytotoxic and stress agents. Moreover, procathepsin D (pCD), secreted from 
cancer cells, might acts as a mitogen on both cancer and stromal cells and 
stimulates their pro-invasive and pro-metastatic properties. Numerous studies 
found that pCD/CD level represents an independent prognostic factor in a 
variety of cancers and is therefore considered to be a potential target of anti-
cancer therapy. One of the possible pitfalls of the analysis of cathepsin D 
expression is due to the fact that there are several simultaneous forms of CD 
in a cell (pCD, intermediate enzymatically active CD and mature heavy and 
light chain CD).133  
The cathepsin D expression evaluation in cancers has been already 
described with particular attention to its possible role as marker of cancer 
status and prognosis, its functional role in cancer progression including 
mitogenic functions, influence on invasion, metastasis, angiogenesis, 
apoptosis and consequently also as a target of cancer therapy.134,135,136 
Although confirmatory data about cathepsin D (and pro-cathepsin D) as 
mitogenic autocrine factors secreted by cancer cells and its involvement in 
angiogenesis and metastatic attitude have already been reported so far, the 
lack of standardization in measurement techniques of pCD/CD, limits their 
current clinical usefulness in oncology.137  
Overall we could conclude that the despite the role of cathepsin D in 
cancer metastasis is actually poorly understood,138 this enzyme is a useful 
marker for identifying breast carcinomas with increased risk of recurrent 
disease and metastasis.139 Cathepsin D is recognized as an independent 
prognostic factor in breast carcinoma because of its impact on the incidence 
of clinical metastasis; its mechanism of action may involve direct digestion of 
the basement membrane, promotion of cell growth, and a decreased contact 
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inhibition.140 This role in cancer metastasis has been studied also in 
melanoma, prostatic carcinoma, and ovarian tumors.  
In our proteomic study cathepsin D resulted three fold less expressed in 
adrenal carcinomas than in adenomas. This data seems to be contradictory 
with respect to the general believing of the literature, which usually describes 
a direct proportional relationship between cathepsin D expression and tumor 
grade. Interestingly in some immunohistochemical studies performed on 
central nervous system (particularly in astrocytomas with higher grade of 
malignancy) and also urological neoplasms cathepsin D has been found 
under-expressed, implying a possible down-regulation of the protein in highly 
malignant tumors with loss of differentiation.141,142 
Moreover in ovarian cancers cathepsin D showed a negative relation to 
p53 expression: this could be another source of explanation of the low levels 
of cathepsin D in our series. In fact it is well known that p53 is generally 
overexpressed in ACCs and moreover the transcription of the cathepsin D 
gene is initiated from several sites, including one that is a start site for an 
estrogen-regulated transcript and both ovarian and adrenocortical cancers may 
secrete estrogens.135,143 
Aldose reductase, a member of aldo-keto reductase superfamily of 
proteins, is the mediator of inflammatory signals induced by growth factors, 
cytokines, chemokines, carcinogens etc. It reduces glucose to sorbitol glucose 
to sorbitol in the presence of NADPH during hyperglycemic conditions and it 
is supposed to play a protective role against toxic aldehydes and free radicals 
derived from lipid peroxidation and steroidogenesis that could affect cell 
growth/differentiation when accumulated. More than 250 publications result 
from searching the literature by using keywords “aldose reductase” and 
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“cancer”. Nonetheless very few of these publications are actually referred to 
AR and various forms of cancer. Aldose reductase is found more commonly 
over-expressed in cancers such as lung, breast, prostate, cervix, ovarian and 
colon; some authors showed that the specific activity of AR was higher in 
tumor areas than in non-tumor regions of tissues.144,145,146  
Inversely in our study this enzyme resulted under-expressed in ACCs 
with regard to ACAs.  Adrenal gland is a major site of AR expression; 
therefore we could expect some variations in its expression in adrenal disease. 
In fact this is not the first time that AR under-expression has been found in 
ACCs: Lefrançois and coll. in fact could demonstrate in a series of 37 
adrenocortical neoplasms (benign, malignant, functioning and non-
functioning) that the majority of ACCs (7/8) exhibited low or hardly 
detectable amounts of AKR1B1 protein: quantification of AR signals showed 
significantly lower concentrations of the enzyme in malignant tumors than in 
normal tissue, adenomas, or Cushing’s hyperplasia (data confirmed also by 
mRNA study). We agree with these authors who highlighted two possible 
reasons for low AR expression in carcinomas: first, chromosomal alterations, 
including mutations or rearrangements, could reduce expression of the gene.  
Unfortunately this is probably only a theoretical suggestion, because no 
chromosomal abnormalities have been described in adrenal tumorigenesis so 
far. Alternatively, inhibition of AR gene expression, in carcinomas, may be 
due to alteration of the mechanisms underlying the control of gene 
expression: one of them could be cAMP action. Interestingly, the transcription 
factor cAMP-responsive element-binding protein (CREB) resulted strongly 
decreased at the protein level in ACCs. Changes in aldose reductase mRNA 
levels in response to cAMP, in parallel with steroidogenic genes, suggest that 
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AR could be considered a marker of adrenocortical cell 
differentiation.147,148,149  
On the contrary, overexpression of aldose reductase and/or aldose 
reductase-like proteins in other cancers such as hepatocellular carcinomas has 
been interpreted as a defense reaction against harmful metabolites produced 
by the growing cancer cells. Overall the authors concluded that it is far to be 
elucidate whether the decrease in AR expression in malignant tumors is 
merely a consequence of a general dedifferentiation of the tumor or whether if 
it contributes to the pathogenesis of the malignancy by promoting, as a 
consequence of lipid peroxidation products accumulation, alterations in cell-
cell communication through progressive loss of gap junctions. Several 
evidences pointed out that AR expression could be chosen as a good 
candidate marker for further studies in ACCs, first of all because 88% of the 
carcinomas exhibit AR protein concentrations below the lowest value 
measured in normal tissues and benign neoplasms: this is reflecting the same 
result we have obtained by proteomic profile. Second, AR is a very stable 
soluble protein whose detection is easy to be performed simply using a 
Western blot analysis, although more sensitive quantitative analysis could be 
easily improved by development of an AR-based RIA or ELISA. Moreover it 
would be worth investigating whether maintaining a high capacity of AR-
dependent detoxication could impair or delay malignant transformation 
process in adrenal cortex.147  
Aldose reductase reduced expression levels have also been reported in 
endometrial cancer, tumors characterized by cell proliferation due to high 
concentrations of estrogens, and decreased cell differentiation due to low 
levels of progesterone and retinoic acid. These tumors are also associated with 
aberrant inflammatory responses and concomitant increased production of 
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prostaglandins. A significantly lower mRNA and protein level of AR in 
endometrial cancerous tissues compared to adjacent endometrium has been 
detected. Immunohistochemistry revealed that the enzyme was present in all 
of the samples (located in epithelial cells of cancerous and control 
endometrial glands). Elevated levels in adjacent non-cancerous tissues could 
be interpreted as the role of AR in the initiation of endometrial cancer more 
than in its progression.149  
Lactate dehydrogenase A catalyzes the inter-conversion of pyruvate 
and L-lactate with concomitant inter-conversion of NADH and NAD+. 
LDHA is found in most somatic tissues, predominantly in muscle tissue and 
tumors, and belongs to the lactate dehydrogenase family. Very recently Liu 
and coll. demonstrated that LDHA is overexpressed in gastric cancers and 
notably targeting this enzyme with its inhibitor (oxamate) they observed the 
decrease of lactate production and, in presence of glucose, the inhibition of 
cell proliferation in a dose-dependent manner. Moreover the pro-apoptotic 
effect of oxamate was further highlighted by flow cytometry.150  
From the clinical point of view it is even more important to know that 
LDHA may modulate (18)F-FDG uptake (e.g. in lung adenocarcinomas) via 
the AKT-GLUT1 pathway and may increase (18)F-FDG accumulation into 
non-small cell lung cancer, possibly by upregulation of GLUT1 expression. 
Based on LDHA expression and on a retrospective radiological clinical study, 
Zhou and coll. could demonstrate that (18)F-FDG PET/CT may predict 
LDHA expression levels and response to anti-LDHA therapy in lung 
adenocarcinoma.151  
As previously mentioned, cancer cells exhibit altered glucose 
metabolism, known as Warburg effect. This effect consists by the increase 
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uptake of glucose and the conversion of glucose to lactate in cancer cells 
under adequate oxygen tension. Recent genetic and metabolic analyses have 
provided insights about the molecular mechanisms of genes that are involved 
in the Warburg effect and tumorigenesis, being LDHA one of these genes 
products. With regard to tumors of the gastrointestinal tract an association 
between overexpression of transcriptional factors, metabolite transporters and 
glycolytic enzymes and both poor prognosis and chemotherapy resistance, has 
been described.152  
Furthermore, also in endocrine oncology, a proteomic approach 
allowed obtaining the same interesting data regarding LDHA overexpression 
in pheochromocytomas and paragangliomas.153  
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CONCLUSIONS 
 
In conclusion, our computerized morphometric model showed to be an 
efficient and simple method of quantification of the morphologic 
characteristics of adrenocortical lesions. It is reproducible and lacks of 
observer or subjective bias. Therefore, it could represent an adjunctive tool to 
complement conventional histological analysis to conceivably enhance the 
reliability and uniformity of the diagnostic evaluation of adrenocortical 
nodular lesions. Moreover, data obtained could be integrated and coupled in a 
dedicated software with classical microscopic pathology assessment to supply 
further information to conventional histological analysis of the adrenocortical 
lesions. 
It is known that the comparisons between adenomatous tissues 
generally consisting of a monoclonal, homogeneous tumor cell population 
and normal adrenal or carcinomas, represented by various proportions of 
adrenal cell types (ACC often showed a polyclonal cells proliferation pattern), 
may also carry some bias. Nonetheless we believe that the morphological 
analysis of adrenocortical neoplasms, possibly driving in the future to a 
nuclear size distribution evaluation, could represent a step forward for a better 
understanding of this heterogeneous disease.  
Although Ki-67 proliferative activity assessed by the automated system 
was in reasonably good agreement with visual assessment as for diagnostic 
phase, its prognostic value with respect to recurrence-free and cancer-specific 
survival need further investigation and validation studies to be considered 
accurate and effective.  
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Visual methods are used widely in the clinical assessment of Ki-67 
proliferative activity. We recently participated to an international multicentric 
study on classical visual Ki-67 assessment in adrenal cancers under the 
supervision of ENS@T association: centralization of laboratory services and 
increasing workloads may increase the interest also in computerized image 
analysis for the assessment of Ki-67 labeling index.154 Moreover we could 
argue that a morphometric model applied to an IHC study (particularly with 
the assessment of proliferation markers such as Ki-67) and assisted by an 
image analyzer could offer significant advantages, including greater rapidity, 
high reproducibility as well as the possibility of making a digital images 
archive to be shared between different Institutions. 
Although some authors underlined that a human observer may be better 
at recognizing non-tumor or stromal areas in the sample than an image 
analysis algorithm,47 we hypothesize that with a correct mathematical 
algorithm together with an expert operator (who could work also as a tutor for 
other operators) working with a semi-automated system, this obstacle could 
be easily overtaken.  
The genome of a given cell or organism is relatively static, subject to 
epigenetic modulation, whereas the transcriptome and proteome are more 
dynamic, and change with time and conditions reflecting the different state of 
the disease. Indeed, the proteome is much more complex than the 
transcriptome due to post-translational modifications, translocation, protein–
protein interactions and regulation, but otherwise may provide more direct 
information when compared with the transcriptome in relation to oncogenesis. 
An important aim of proteomics is to understand the cellular function at the 
protein level by the dynamic proteome, clarifying the functions of proteins 
and disclosing new biomarkers for disease states. 
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In conclusion, stereology is of great value for quantifying tumor
 elements. For  objective malignancy grading especially assessment of the 
three-dimensional mean nuclear size seems useful. All of these systems and 
methods have a common goal: the standardization of IHC interpretation. 
Standardized, controlled assays, in combination with a device that provides 
quantitative and objective output, can dramatically improve the quality of the 
data obtained from IHC studies. They allow increased sensitivity in scoring 
and provide a more reliable and reproducible analysis of protein expression in 
situ. With the advent of these new systems and a controlled approach, the goal 
of standardizing IHC, from the fixation of tissues to the analysis of IHC 
results, is achievable. 
The retrospective review of the pre-surgical radiological data in light of 
the biomolecular evidences could be used to better characterize the sensitivity 
and specificity of radiological imaging techniques.  
On the basis of recent advantages obtained with the revision of the 
staging of adrenal cortical carcinoma proposed by ENSAT we believe that a 
reconsideration of the histopathological features of these tumors and the 
identification of parameters that can clearly identify moderately malignant 
neoplasms from more aggressive histotypes is absolutely needed: an uncertain 
biological behavior is directly related to a long follow-up, with the consequent 
clinical relapses, economic and psychosocial. 
The revaluation of the Weiss criteria through the use of new 
technologies (such as mathematical modeling and image analysis) and the 
identification of new histological parameters to be used in the analysis of 
fresh tissues might help to create a prognostic stratification of ACCs with 
clear advantages for the clinical management and a new decision tree for this 
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disease (choice of targeted adjuvant chemotherapy, radiotherapy, properly 
"timing" the follow-up, etc.). Furthermore, although the translation of results 
from research to clinical practice may not be immediate, we are confident that 
a further proteomic characterization of ACC may allow the design of new 
therapies directed to target molecules (possibly also radiolabelled) that can 
provide an additional therapeutic or diagnostic option for these patients. 
 
 
 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 85 - 
 
 
 
 
REFERENCES 
 
 
1. Barzon L, Sonino N, Fallo F, Palù G, Boscaro M. Prevalence and natural 
history of adrenal incidentaloma. Eur J Endocrinol 2003; 149(4): 273-285 
2. Cicala MV, Sartorato P, Mantero F. Incidentally discovered masses in 
hypertensive patients. Best Pract Res Clin Endocrinol Metab 2006; 20(3): 
451-466. 
3. Grumbach MM, Biller BMK, Braunstein GD, Campbell KK, Carney JA, 
Godley PA, Harris EL, Lee JKT, Oertel YC, Posner MC, Schlechte JA, 
Wleand HS. Management of the clinically inapparent adrenal mass 
(“incidentaloma”). Ann Intern Med 2003; 138(5): 424-429 
4. Aron DC. The adrenal incidentaloma: Disease of modern technology and 
public health problem. Rev Endocr Metab Disord 2001; 2(3): 335-342 
5. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, 
Borasio P, Fava C, Dogliotti L,  Scagliotti GV, Angeli A, Terzolo M. 
Prevalence of adrenal incidentaloma in a contemporary computerized 
tomography series. J Endocrinol Invest 2006; 29(4): 298-302. 
6. Young WF Jr. Clinical practice. The incidentally discovered adrenal 
mass. N Engl J Med 2007; 356(6): 601-610. 
7. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and 
other surgically corretable forms of primary aldosteronism. Orphanet J Rare 
Dis 2010  
8. Mazzuco TL, Bourdeau I, Lacroix A. Adrenal incidentalomas and 
subclinical Cushing's syndrome: diagnosis and treatment. Curr Opin 
Endocrinol Diabetes Obes 2009; 16(3): 203-210 
9. Pantalone Km, Gopan T, Remer EM, Faiman C, Ioachimescu AG, Levin 
HS, Siperstein A, Berber E, Shepardson LB, Bravo EL, Hamrahian AH. 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 86 - 
Change in adrenal mass size as a predictor of malignant tumor. Endocr Pract. 
2010 Jul-Aug;16(4):577-87 
10. NIH state-of-the-science statement on management of the clinically 
inapparent adrenal mass (incidentaloma”). NIH Consens State Sci Statements 
2002; 19(2): 1-25 
11. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease 
at presentation and outcome for adrenocortical carcinoma: have we made 
progress? World J Surg. 2006 May;30(5):872-8  
12. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J 
Clin Endocrinol Metab 2006; 91(6): 2027-2037 
13. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol 
2003; 15(1): 84-90 
14. Luton JP, Martinez M, Coste J, Bertherat J. Outcome in patients with 
adrenal incidentaloma selected for surgery: an analysis of 88 cases 
investigated in a single clinical center. Eur J Endocrinol 2000; 143(1): 111-
117 
15. Singh PK, Buch HN. Adrenal incidentaloma: evaluation and 
management. J Clin Pathol 2008; 61(): 1168-1173 
16. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of 
adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009; 23(2): 
233-243 
17. Roman S. Adrenocortical carcinoma. Curr Opin Oncol 2006; 18(1): 36-
42 
18. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, 
Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B. Limited 
prognostic value of the 2004 International Union Against Cancer staging 
classification for adrenocortical carcinoma. Proposal for a revised TNM 
classification. Cancer 2009; 115(2): 243-250  
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 87 - 
19. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, 
Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI. The 
European Network for the Study of Adrenal Tumors staging system is 
prognostically superior to the International Union Against Cancer staging 
system: a North American validation. Eur J Cancer 2010; 46(4): 713-719 
20. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM. 
Needle biopsy of incidentally discovered adrenal masses is rarely informative 
and potentially hazardous. Surgery 2007; Lösch (4): 497-504 
21. Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the 
evaluation of adrenal neoplasm. A decade of experience. Arch Surg 2009; 
144(5): 465-470 
22. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, 
Ballotta E. Surgical versus conservative management for subclinical cushing 
syndrome in adrenal incidentalomas: a prospective randomized study. Annals 
of Surgery 2009; 249(3): 388-391 
23. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, 
Coletti F, Iorio L, Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti 
M, Beck-Peccoz P, Arosio M, Ambrosi B, Trischitta V, Scillitani A. 
Beneficial metabolic effects of prompt surgical treatment in patients with an 
adrenal incidentaloma causing biochemical hypercortisolism. J Clin 
Endocrinol Metab 2010; 95(6): 2736-2745 
24. Shen WT, Sturgeon C, Duh QY. From incidentaloma to adrenocortical 
carcinoma: the surgical management of adrenal tumors. J Surg Oncol 2005; 
89(3):186–192 
25. Weiss LM. Comparative histologic study of 43 metastasizing and 
nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8(3): 163-
169 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 88 - 
26. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical 
neoplasms: 25 years later. Hum Pathol 2009; 40(6): 757-768 
27. Sasano H, Suzuki T, Moriya T. Discerning malignancy in resected 
adrenocortical neoplasm. Endocr Pathol 2001; 12(4): 397-406 
28. McNicol AM. Assessment of malignancy in adrenal cortical tumors. 
Endocr Pathol 2006; 17(2): 131-136  
29. Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, 
Wemeau JL, Lecomte-Houcke M, Leteurtre E. Weiss system revisited. A 
clinocopathologic and immunohistochemical study of 49 adrenocortical 
tumors. Am J Surg Pathol 2002; 26(12): 1612-1619 
30. van’t Sant HP, Bouvy ND, Kazemier G, Bonjer HJ, Hop WCJ, Feelders 
RA, de Herder WW, de Krijger RR. The prognostic value of two different 
histopathological scoring systems for adrenocortical carcinomas. 
Histopathology 2007; 51(2): 239-245 
31. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological 
and molecular features of adrenocortical carcinoma: an update. J Clin Pathol. 
2008 Jul;61(7):787-93. Review 
32. Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, 
Terzolo M, Berruti A, Papotti M. Clinicopathological study of a series of 92 
adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm 
to prognostic stratification. Histopathology. 2009 Nov;55(5):535-43 
33. Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso 
R, Dalino Ciaramella P, Ventura L, Gambacorta M, Dei Tos AP, Loli P, 
Mannelli M, Mantero F, Berruti A, Terzolo M, Papotti M. The reticulin 
algorithm for adrenocortical tumor diagnosis: a multicentric validation study 
on 245 unpublished cases. Am J Surg Pathol. 2013 Sep;37(9):1433-40 
34. Scholzen T, Gerdes J. The Ki-67 protein. From the known and the 
unknown. J Cell Physiol 2000; 182(3): 311-322 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 89 - 
35. Mitra AV, Jameson C, Barbachano Y, Sodha N, Kote-Jarai Z, Javed A, 
Bancroft E, Fletcher A, Cooper C, Peock S. Elevated expression of Ki-67 
identifies aggressive prostate cancers but does not distinguish BRCA1 or 
BRCA2 mutation carriers. Oncol Rep 2010; 23(2): 299-305  
36. Karanikas G, Koronakis N, Lagoudianakis EE, Grosomanidis D, 
Karavitis G, Koukoutsis I, Pappas A, Kotzadimitriou K, Papadima A, 
Chrysikos J, Zografos G, Xepapadakis G, Manouras A. The value of 
proliferation indexes in breast cancer. Eur J Gynaecol Oncol 2010; 31(2): 
181-184 
37. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, 
Thompson N, Lloyd RV. Immunohistochemical assessment of proliferative 
activity in adrenocortical neoplasms. Mod Pathol 1993; 6(6): 663-668 
38. Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, Alì A, Paccotti 
P, Porpiglia F, Fontana D, Angeli A. Immunohistochemical assessment of Ki-
67 in the differential diagnosis of adrenocortical tumors. Urology 2001; 57(1): 
176-182 
39. De Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, 
Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M: Ki-
67 as prognostic marker in early breast cancer: a meta-analysis of published 
studies involving 12,155 patients. Br J Cancer 2007 
40. Morimoto R, et al. Immunohistochemistry of a proliferation marker 
Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a 
predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008 
Mar;55(1):49-55 
41. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and 
quantitative analysis of protein expression. Arch Pathol Lab Med. 2006 
Jul;130(7):1026-30 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 90 - 
42. Kolles H, Forderer W, Bock R, Feiden W: Combined Ki-67 and Feulgen 
stain for morphometric determination of the Ki-67 labelling index. 
Histochemistry 1993, 100:293-296; Bloom K, Harrington D: Enhanced 
accuracy and reliability of HER-2/neu immunohistochemical scoring using 
digital microscopy. Am J Clin Pathol 2004, 121:620-630 
43. Stromberg S, Bjorklund MG, Asplund C, Skollermo A, Persson A, 
Wester K, Kampf C, Nilsson P, Andersson AC, Uhlen M, et al: A high-
throughput strategy for protein profiling in cell microarrays using automated 
image analysis. Proteomics 2007, 7:2142-2150 
44. Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, 
McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, et al: Automated 
quantitative analysis of estrogen receptor expression in breast carcinoma does 
not differ from expert pathologist scoring: a tissue, Breast Cancer Res Treat. 
2008 Aug;110(3):417-26 
45. Camp RL, Chung GG, Rimm DL: Automated subcellular localization 
and quantification of protein expression in tissue microarrays. Nat Med 2002, 
8:1323-1327 
46. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, 
Carrier M, Huntsman D, Aparicio S: Inter-observer reproducibility of HER2 
immunohistochemical assessment and concordance with fluorescent in situ 
hybridization (FISH): pathologist assessment compared to quantitative image 
analysis. BMC Cancer 2009, 9:165 
47. Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, 
Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J.r. 
Development and evaluation of a virtual microscopy application for 
automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol. 
2011 Jan 25;11:3 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 91 - 
48. Weibel ER. 1989. Measuring through the microscope: development and 
evolution of stereological methods. J Microsc 155 (Pt 3): 393-403 
49. Andersen BB and Pakkenberg B. 2003. Stereolog- ical quantitation in 
cerebella from people with schizophrenia. Br J Psychiatry 182: 354-361 
50. Aherne WA and Dunnill MS. 1982. Morphometry. London: Edward 
Arnold, 205 p 
51. Mandarim-de-Lacerda CAAn Acad Bras Cienc. Stereological tools in 
biomedical research. 2003 Dec;75(4):469-86 
52. Gundersen HJ and Osterby R. 1981. Optimizing sam- pling efficiency of 
stereological studies in biology: or ‘do more less well!’ J Microsc 121: 65-73. 
53. Gil J1, Wu H, Wang BY. Image analysis and morphometry in the 
diagnosis of breast cancer. Microsc Res Tech. 2002 Oct 15;59(2):109-18. 
54. Tissier F, Aubert S, Leteurtre E, Al Ghuzlan A, Patey M, Decaussin M, 
Doucet L, Gobet F, Hoang C, Mazerolles C, Monges G, Renaudin K, Sturm 
N, Trouette H, Vacher-Lavenu MC, Viallon V, Baudin E, Bertagna X, Coste 
J, Libe R. Am J Surg Pathol. 2012 Aug;36(8):1194-201. Adrenocortical 
tumors: improving the practice of the Weiss system through virtual 
microscopy: a National Program of the French Network INCa-COMETE. 
55. Deligdisch L, Einstein AJ, Guera D, Gil J. 1995. Ovarian dysplasia in 
epithelial inclusion cysts: a morphometric approach using neural networks. 
Cancer 76:1027–1034, Unger PD, Watson CW, Liu Z, Gil J. 1993. 
Morphometric analysis of neoplastic renal aspirates and benign renal tissue. 
Anal Quant Cytol Histol 15:61–66 
56. Wu HS, Gil J, Barba J. 1998a. Optimal segmentation of cell images. IEE 
Proc Vis Image Signal Proc 145:50–56. 
57. Ladekarl M Objective malignancy grading: a review emphasizing 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 92 - 
unbiased stereology applied to breast tumors. APMIS Suppl. 1998;79:1-34 
58. Diest PJ, Baak JPA. Quantitative cyto-andhistoprog- nosis in breast 
cancer. Amsterdam: Elsevier Science Publishers BY, 1992 
59. Haapasalo H,Collan Y,Atkin NB,Pesonen E,Seppa A: Prognosis of 
ovarian carcinomas: prediction by histo- quantitative methods. 
Histopathology 15:167-178,1989 
60. Myhre Jensen 0, Hsgh H, 0stgaard SE, Nordentoft AM, Sneppen O: 
Histopathological grading of soft tissue tumours. Prognostic significance in a 
prospective study of 278 consecutive cases. J Patholl6319-24,1991 
61. Nielsen K, Colstrup H, Nilsson T, Gundersen HJG: Stereological 
estimates of nuclear volume correlatedwith histopathological grading and 
prognosis of bladder tumour.Virchows Arch (Cell Pathol ) 52:41-54,1986 
62. Ssrensen FB: Quantitative analysis of nuclear size for objective 
malignancy grading: a review with emphasis on new, unbiased stereologic 
methods. Lab Invest 664-23,1992 
63. Ladekarl M, Baek-HansenT, Henrik-Nielsen R, Mourit- Zen C, 
Henriques U, Smensen FB: Objective malignancy grading of squamous cell 
carcinomas of the lung. Stereologic estimates of mean nuclear size are of 
prog- nostic value, independent of clinical disease stage. Can- cer 76797-
802,1995 
64. Artacho-Perula E, Roldan-Villalobos R, Lopez-Rubio F,Vaamonde-
Lemos R: Stereological estimates of nu- clear volume in carcinoma ofthe 
ampulla ofVater. His- topathology 21:241-248,1992 
65. Słodkowska J, Markiewicz T, Grala B, Kozłowski W, Papierz W, 
Pleskacz K, Murawski P. Accuracy of a remote quantitative image analysis in 
the whole slide images. Diagn Pathol. 2011 Mar 30;6 Suppl 1:S20 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 93 - 
66. Ananthanarayanan V1, Deaton RJ, Amatya A, Macias V, Luther E, 
Kajdacsy-Balla A, Gann PH. Subcellular localization of p27 and prostate 
cancer recurrence: automated digital microscopy analysis of tissue 
microarrays. Hum Pathol. 2011 Jun;42(6):873-81. 
67. Seleni-Balafouta S, Kavantzas N, Paraskevakou H, Davaris P. 
Computerized morphometric study on fine needle aspirates of cellular 
follicular lesions of the thyroid. Anal Quant Cytol Histol 2000; 22: 323–6 
68. Artacho-Perula E, Roldan-Villalobos R, Blanco-Garcia F, Blanco-
Rodriguez A. Objective differential classification of thyroid lesions by 
nuclear quantitative assessment; Histol Histo- pathol 1997; 12: 425–31  
69. Sheng-Lan Wang, Ming-Tsang Wu, Sheau-Fang Yang, Hon-Man Chan 
and Chee-Yin Chai. Computerized nuclear morphometry in thyroid follicular 
neoplasms Pathology International 2005; 55: 703–706 
70. Hoffman K1, Gil J, Barba J, Liu Z, Pertsemlidis D, Kaneko M, Unger P. 
Morphometric analysis of benign and malignant adrenal pheochromocytomas. 
Arch Pathol Lab Med. 1993 Mar;117(3):244-7. 
71. Trifunović S\, Manojlović-Stojanoski M, Ajdžanović V, Nestorović N, 
Ristić N, Medigović I, Milošević V. Effects of genistein on stereological and 
hormonal characteristics of the pituitary somatotrophs in rats. Endocrine. 
2014 Dec;47(3):869-77 
72. Scarpelli M, Montironi R, Mazzucchelli R, Thompson D, Bartels PH. 
Distinguishing cortical adrenal gland adenomas from carcinomas by their 
quantitative nuclear features. Anal Quant Cytol Histol. 1999 Apr;21(2):131-8. 
73. Shirata NK, Sredni ST, Castelo A, Santinalli A, Mendonça B, Montironi 
R, Longatto Filho A, Zerbini MCN. Texture Image Analysis in 
Differentiating Malignant from Benign Adrenal Cortical Tumors in Children 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 94 - 
and Adults. Anticancer Research 29: 3365-3368 (2009) 
74. Dhall D, Frishberg DP, Galliano G, et al. Interobserver variability in 
assessing Ki67 proliferative index in gastrointestinal well-differentiated 
neuroendocrine neoplasms. Mod Pathol. 2009; 22:116A 
75.  David S. Klimstra et al. Pathology Reporting of Neuroendocrine 
Tumors: Application of the Delphic Consensus Process to the Development 
of a Minimum Pathology Data Set. Am J Surg Pathol   Volume 34, Number 3, 
March 2010 
76. Lejeune M, Jaen J, Pons L, et al. Quantification of diverse subcellular 
immunohistochemical markers with clinicobiological relevancies: validation 
of a new computer-assisted image analysis procedure. J Anat. 2008;212:868–
878. 
77.  Mylona E, Nomikos A, Alexandrou P, Giannopoulou I, Keramopoulos 
A, Nakopoulou L. Lymphatic and blood vessel morphometry in invasive 
breast carcinomas: relation with proliferation and VEGF-C and -D proteins 
expression. 51 Histol Histopathol. 2007 Aug;22(8):825-35. 
78.  Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF. Intratumoral 
neutrophils: A poor prognostic factor for hepatocellular carcinoma following 
resection. J Hepatol. 2011 Mar;54(3):497-505. 
79. Calvo KR1, Liotta LA, Petricoin EF. Clinical proteomics: from 
biomarker discovery and cell signaling profiles to individualized personal 
therapy. Biosci Rep. 2005 Feb-Apr;25(1-2):107-25. 
80. Magdeldin S, Enany S, Yoshida Y, Xu B, Zhang Y, Zureena Z, 
Lokamani I, Yaoita E, Yamamoto T. Basics and recent advances of two 
dimensional-polyacrylamide gel electrophoresis. Clin Proteomics. 2014 Apr 
15;11(1):16.  
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 95 - 
81. Görg A, Drews O, Lück C, Weiland F, Weiss W. 2-DE with IPGs. 
Electrophoresis. 2009 Jun;30 Suppl 1:S122-32. 
82. Walker JM. The proteomics protocol handbook. Humana Press, 2005 
83. Unlü M, Morgan ME, Minden JS. Difference gel electrophoresis: a 
single gel method for detecting changes in protein extracts. 
Electrophoresis.1997 Oct;18(11):2071-7. 
84. Appel RD, Palagi PM, Walther D, et al. Melanie II-a third-generation 
software package for analysis of two-dimensional electrophoresis images: I. 
Features and user interface. Electrophoresis 1997; 18:2724. 
85. Ko KH, Kwon CI, Park SH, Han NY, Lee HK, Kim EH, Hahm KB. 
Application of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight 
Imaging Mass Spectrometry (MALDI-TOF IMS) for Premalignant 
Gastrointestinal Lesions. Clin Endosc. 2013 Nov;46(6):611-9. 
86. Bairoch A1, Apweiler R. The SWISS-PROT protein sequence data bank 
and its supplement TrEMBL in 1998. Nucleic Acids Res. 1998 Jan 
1;26(1):38-42. 
87. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex 
protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 
17:994. 
88. Chaurand P, DaGue BB, Pearsall RS, et al. Profiling proteins from 
azoxymethane-induced colon tumors at the molecular level by matrix-assisted 
laser desorption/ionization mass spectrometry. Proteomics 2001; 1:1320. 
89. Chaurand P, Schwartz SA, Caprioli RM. Imaging mass spectrometry: a 
new tool to investigate the spatial organization of peptides and proteins in 
mammalian tissue sections. Curr Opin Chem Biol 2002; 6:676. 
90. Pusch W, Flocco MT, Leung SM, et al. Mass spectrometry-based 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 96 - 
clinical proteomics. Pharmacogenomics 2003; 4:463. 
91. Altelaar AF1, Munoz J, Heck AJ. Next-generation proteomics: towards 
an integrative view of proteome dynamics. Nat Rev Genet. 2013 
Jan;14(1):35-48 
92. Anderson L, Seilhamer J. A comparison of selected mRNA and protein 
abundances in human liver. Electrophoresis 1997; 18:533. 
93. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA 
expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1:304. 
94. Bichsel VE, Liotta LA, Petricoin EF 3rd. Cancer proteomics: from 
biomarker discovery to signal pathway profiling. Cancer J 2001; 7:69 
95. Wright GL Jr. Two-dimensional acrylamide gel electrophoresis of 
cancer-patient serum proteins. Ann Clin Lab Sci 1974; 4:281. 
96. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 
2000; 405:837 
97. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour 
subsets in non-small-cell lung cancer. Lancet 2003; 362:433. 
98. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with 
survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003; 100:13537. 
99. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for 
survival and time to progression in non-small cell lung cancer (NSCLC) 
patients treated with erlotinib and bevacizumab. Lung Cancer 2010; 69:337. 
100. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate 
cancer. N Engl J Med 2005; 353:1224 
101. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 97 - 
Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum 
protein fingerprinting coupled with a pattern-matching algorithm 
distinguishes prostate cancer from benign prostate hyperplasia and healthy 
men. Cancer Res. 2002;62(13):3609 
102. Albitar M, Potts SJ, Giles FJ, et al. Proteomic-based prediction of 
clinical behavior in adult acute lymphoblastic leukemia. Cancer 2006; 
106:1587 
103. Olsen L, Campos B, Winther O, Sgroi DC, Karger BL, Brusic V. Tumor 
antigens as proteogenomic biomarkers in invasive ductal carcinomas. BMC 
Med Genomics. 2014 Dec 8;7(Suppl 3):S2 
104. Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet 
P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I. Specific 
MALDI imaging and profiling for biomarker hunting and validation: 
fragment of the 11S proteasome activator complex, Reg alpha fragment, is a 
new potential ovary cancer biomarker. J Proteome Res. 2007 
Nov;6(11):4127-34 
105. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, 
Heinz DE, Shroyer KR, Duncan MW, Haugen BR 2006 Quantitative and 
qualitative differences in protein expression between papillary thyroid 
carcinoma and normal thyroid tissue. Mol Carcinog  45:613– 626 
106. Ribeiro-Oliveira A Jr, Franchi G, Kola B, Dalino P, Pinheiro SV, 
Salahuddin N, Musat M, Góth MI, Czirják S, Hanzély Z, da Silva DA, 
Paulino E Jr, Grossman AB, Korbonits M. Protein western array analysis in 
human pituitary tumours: insights and limitations. Endocr Relat Cancer. 2008 
Dec;15(4):1099-114 
107. Patterson EE1, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 98 - 
profiling of adrenocortical tumors reveals miR-483 as a marker of 
malignancy. Cancer. 2011 Apr 15;117(8):1630-9. 
108.  De Reyniès A, Assiè G, Rickman DS, Tissier F, Groussin L, Rene'-
Corail F, Dousset B, Bertagna X, Clauser E, Berterat J. Gene expression 
profiling reveals a new classification of adrenocortical tumors and identifies 
molecular predictors of malignancy and survival. J Clin Oncol. 2009 Mar 
1;27(7):1108-15 
109. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, 
Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, 
Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, 
Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, 
Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, 
Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic 
characterization of adrenocortical carcinoma. Nat Genet. 2014 Jun;46(6):607-
12 
110. Kjellin H, Johansson H, Höög A, Lehtiö J, Jakobsson PJ, Kjellman M. 
Differentially expressed proteins in malignant and benign adrenocortical 
tumors. PLoS One. 2014 Feb 3;9(2) 
111. Li F, Ren W, Zhao Y, Fu Z, Ji Y, et al. (2012) Downregulation of 
GRIM-19 is associated with hyperactivation of p-STAT3 in hepatocellular 
carcinoma. Med Oncol 29: 3046–3054 
112. Moreira S, Correia M, Soares P, Maximo V (2011) GRIM-19 function in 
cancer development. Mitochondrion 11: 693–699. 
113. Máximo V1, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro 
T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simões M. 
Somatic and germline mutation in GRIM-19, a dual function gene involved in 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 99 - 
mitochondrial metabolism and cell death, is linked to mitochondrion-rich 
(Hurthle cell) tumours of the thyroid. Br J Cancer. 2005 May 23;92(10):1892-
8. 
114. Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, 
Piergrossi P, Brunetti E, Simmaco M, Toscano V. Modulation of proteomic 
profile in H295R adrenocortical cell line induced by mitotane. Endocr Relat 
Cancer. 2008 Mar;15(1):1-10 
115. Sheibani, K., Battifora, H., Burke, J. S., and Rappaport, H. (1986) Leu-
M 1 antigen in human neoplasms: an immunohistologic study of 400 cases. 
Am. J. Surg. Pathol. 10, 227-236 
116. Gordon, H and Sweet, H.H.  1936 A simple method for the silver 
impregnation of reticulin. American Journal of Pathology, V12, p545 
117. Vertemati M, Vizzotto L, Moscheni C, Dhillon A, Dhillon A, Quaglia A. 
A morphometric model to minimize subjectivity in the histological 
assessment of hepatocellular carcinoma and its precursors in cirrhosis. 
Microsc Res Tech. 2008 Aug;71(8):606-13 
118. Weibel ER, Kistler GS, Scherle WF. Practical stereological methods for 
morphometric cytology. The Journal of Cell Biology, Vol 30, 1966, p 23-38. 
119. Rabilloud, T., Adessi, C., Giraudel, A., Lunari, J., Improvement of the 
solubilization of proteins in two-dimensional electrophoresis with 
immobilized pH gradients. Electrophoresis 1997, 18, 307–316.]  
120. Karp, N. A., Lilley, K. S., Maximizing sensitivity for detecting changes 
in protein expression: Experimental design using minimal CyDyes. 
Proteomics 2005, 5, 3105–3115]. 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 100 - 
121. Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, 
Allolio B, Reincke M. Discerning malignancy in adrenocortical tumors: are 
molecular markers useful? Eur J Endocrinol 2001; 145(3): 335-341. 
122. Stojadinovic A, et al. Adrenocortical adenoma and carcinoma: 
histopathological and molecular comparative analysis. Mod Pathol. 2003 
Aug;16(8):742-51 
123. Menter DG, Hoque A, Motiwala N, Sahin AA, Sneige N, Lieberman R, 
Lippman SM.  Computerized image analysis of Ki-67 in ductal breast 
carcinoma in situ. Anal Quant Cytol Histol. 2001 Jun;23(3):218-28 
124. Dhall D, Frishberg DP, Galliano G, et al. Interobserver variability in 
assessing Ki67 proliferative index in gastrointestinal well-differentiated 
neuroendocrine neoplasms. Mod Pathol. 2009; 22:116A 
125. Nafe R, Franz K, Schlote W, Schneider B. Morphology of tumor cell 
nuclei is significantly related with survival time of patients with 
glioblastomas. Clin Cancer Res. 2005 Mar 15;11(6):2141-8. 
126. Coventry BJ, Weightman MJ, Skinner JM, Bradley J. Improving 
evaluation of the distribution and density of immunostained cells in breast 
cancer using computerized video image analysis. Cancer Manag Res. 
2011;3:101-8. 
127. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target 
for cancer therapy. Cell Mol Life Sci. 2011 Sep;68(18):3033-46 
128. Huang L, Xu A, Liu S, Liu W, Li T. Cancer-associated fibroblasts in 
digestive tumors. World J Gastroenterol. 2014 Dec 21;20(47):17804-17818 
129. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KH 
and Kuerer HM. Proteomic analysis of nipple aspirate fluid from women with 
early-stage breast cancer using isotope-coded affinity tags and tandem mass 
spectrometry reveals differential expression of vitamin D binding protein. 
BMC Cancer 2006, 6:68 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 101 - 
130. Eisman JA, Suva LJ, Sher E, Pearce PJ, Funder JW, Martin TJ: 
Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer. 
Cancer Res 1981, 41:5121-5124 
131. Freake HC, Abeyasekera G, Iwasaki J, Marcocci C, MacIntyre I, 
McClelland RA, Skilton RA, Easton DF, Coombes RC: Measure- ment of 
1,25-dihydroxyvitamin D3 receptors in breast can- cer and their relationship 
to biochemical and clinical indices. Cancer Res 1984, 44:1677-1681 
132. Yamamoto N, Suyama H, Yamamoto N, Ushijima N Int J Cancer. 
Immunotherapy of metastatic breast cancer patients with vitamin D-binding 
protein-derived macrophage activating factor (GcMAF). 2008 Jan 
15;122(2):461-7 
133. Benesa P, Vetvickab V and Fusekc M. Cathepsin D – many functions of 
one aspartic protease. Crit Rev Oncol Hematol. 2008 October ; 68(1): 12–28 
134. Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of 
transfected cathepsin D in transformed cells increases their malignant 
phenotype and metastatic potency. Oncogene 1990;5:1809–1814 
135. Lösch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat 
R, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with 
p53 expression and microvessel density. Gynecol Oncol 2004;92:545–552 
136. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in 
node-negative breast cancer: a review of studies with sample size more than 
200 and follow-up more than 5 years. Ann Surg 2002;235:10–26 
137. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. 
American Society of Clinical Oncology 2007 update of recommendations for 
the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287–5312 
138. Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis: a 
protease and a ligand. APMIS. 1999;107:86-95 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 102 - 
139. Leto G, Gebbia N, Rausa L, et al. Cathepsin D in the malignant 
progression of neoplastic diseases. Anticancer Res. 1992;12:235-240 
140. Rochefort H, Garcia M, Glondu M, et al. Cathepsin D in breast cancer: 
mechanisms and clinical applications: a 1999 overview. Clin Chim Acta. 
2000;291:157-170 
141. Warich M, von Bossanyi P, Dietzmann K. Expression of cathepsin D in 
human astrocytic neoplasias. Gen Diagn Pathol. 1995;141:93-96 
142. Dickinson AJ, Fox SB, Newcomb PV, Persad RX, Sibley GN and Harris 
AL. An immunohistochemical and prognostic evaluation of cathepsin D 
expression in 105 bladder carcinomas. The Journal of Urol, July 1995, vol 
154, issue 1, p 237-41 
143. Arola J, Salmenkivi K, Liu J, Kahri AI, Heikkilä P. p53 and Ki67 in 
adrenocortical tumors. Endocr Res. 2000 Nov;26(4):861-5.  
144. Saraswat M, Mrudula T, Kumar PU, Suneetha A, Rao TS, Srinivasulu 
M, Reddy B. Overexpression of aldose reductase in human cancer tissues. 
Med Sci Monit. 2006; 12:CR525– 529 
145. Lau AT, Wang Y, Chiu JF. Reactive oxygen species: current knowledge 
and applications in cancer research and therapeutic. J Cell Biochem. 2008; 
104:657–667 
146. Tammali R, Srivastava SK, Ramana KV. Targeting Aldose Reductase 
for the Treatment of Cancer. Curr Cancer Drug Targets. 2011 June; 11(5): 
560–571 
147. Lefrançois-Martinez AM, Bertherat J, Val P, Tournaire C, Gallo-Payet 
N, Hyndman D, Veyssière G, Bertagna X, Jean C, Martinez A. Decreased 
expression of cyclic adenosine monophosphate- regulated aldose reductase 
(AKR1B1) is associated with malignancy in human sporadic adrenocortical 
tumors. J Clin Endocrinol Metab. 2004; 89:3010–3019 
Paolo DALINO CIARAMELLA – DIAGNOSIS AND PROGNOSIS OF ADRENAL BENIGN 
AND MALIGNANT TUMORS: NEW INSIGHTS FROM A COMPUTERIZED OPERATOR-
INDEPENDENT MORPHOMETRIC MODEL AND PROTEOMIC EXPRESSION 
 
- 103 - 
148. Rosenberg D, Groussin L, Jullian E, Perlemoine K, Medjane S, Louvel 
A, Bertagna X, Bertherat J 2003 Transcription factor 3,5-cyclic adenosine 5- 
monophosphate-responsive element-binding protein (CREB) is decreased 
during human adrenal cortex tumorigenesis and fetal development. J Clin 
Endocrinol Metab 88:3958 –3965 
149. Hevir N, Sinkovec J, Lanišnik Rižner T. Decreased levels of AKR1B1 
and AKR1B10 in cancerous endometrium compared to adjacent non-
cancerous tissue. Chem Biol Interact. 2013 Feb 25;202(1-3):226-33 
150. Liu X, Yang Z, Chen Z, Chen R, Zhao D, Zhou Y, Qiao L. Effects of the 
suppression of lactate dehydrogenase A on the growth and invasion of human 
gastric cancer cells. Oncol Rep. 2015 Jan;33(1):157-62 
151. Zhou X, Chen R, Xie W, Ni Y, Liu J, Huang G. Relationship between 
18F-FDG accumulation and lactate dehydrogenase a expression in lung 
adenocarcinomas. J Nucl Med. 2014 Nov;55(11):1766-71 
152. Sawayama H, Ishimoto T, Sugihara H, Miyanari N, Miyamoto Y, Baba 
Y, Yoshida N, Baba H. Clinical impact of the Warburg effect in 
gastrointestinal cancer (review). Int J Oncol. 2014 Oct;45(4):1345-54 
153. Fliedner SM, Kaludercic N, Jiang XS, Hansikova H, Hajkova Z, 
Sladkova J, Limpuangthip A, Backlund PS, Wesley R, Martiniova L, 
Jochmanova I, Lendvai NK, Breza J, Yergey AL, Paolocci N, Tischler AS, 
Zeman J, Porter FD, Lehnert H, Pacak K. Warburg effect's manifestation in 
aggressive pheochromocytomas and paragangliomas: insights from a mouse 
cell model applied to human tumor tissue. PLoS One. 2012;7(7) 
154. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology-
taking molecular pathology into a new dimension. Nat Rev Clin Oncol. 2009 
Aug;6(8):455-64 
155.  
